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ABSTRACT 
            The application of magnetic resonance imaging (MRI) to non-invasively assess disease 
biomarkers has been hampered by lack of desired contrast agents with high relaxivity, targeting 
capability, and optimized pharmacokinetics. We developed a novel MRI probe which targets  
HER2, a biomarker for various cancers and a target for anti-cancer therapies. This multimodal 
HER2-targeted MRI probe integrates a rationally designed protein contrast agent with a high 
affinity HER2 affibody and near IR dye. Our probe can differentially monitor tumors with differ-
ent HER2 levels in both cells and xenograft mice. In addition to its 10-fold higher dose efficiency 
compared to clinically-approved agent DTPA, our developed agent also exhibits advantages in 
crossing the endothelial boundary, tissue distribution, and tumor tissue retention as demon-
strated by even distribution of the imaging probe across the entire tumor mass. Additionally, a 
second series of protein contrast agents that included affibody against EFGR developed with 
the capability to specifically target EGFR.  These contrast agents have been utilized to monitor 
drug treatments and quantitatively analyze biomarker expression level. Furthermore, we antic-
ipate these agents will provide powerful tools for quantitative assessment of molecular mark-
ers, and improved resolution for diagnosis, prognosis and drug discovery. 
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Chapter 1. INTRODUCTION 
1.1 Cancer as human diseases 
Cancer is caused by cells that grow uncontrolled and do not die.  Normally, the cells in 
the human body will follow a rule of growth, division, and death.  Programmed cell death is 
called apoptosis [1]. When this process is broken, cancer will form. Unlike regular cells, cancer 
cells do not experience programmatic death and instead continue to grow and divide. This leads 
to a mass of abnormal cells that grows out of control. In addition, cancer progression through 
different stages causes invasiveness and metastasis [2] 
In nowadays, cancer has been one of the most common human diseases, 23% of which 
will cause death. More than 30% people in the world will receive cancer diagnosis during their 
life time [3]. As shown in Figure 1.1, breast cancer and prostate cancer have highest occurrence 
among all the cancers also with relatively high death rate [4]. Cancer diagnosis is mainly 
achieved by X-ray or biopsy. For example, breast cancer was also been detected by mammo-
graphy since 1980s. 
Prognosis is a prediction of probable outcome of a disease [5].Since a lot of factors of 
individuals will affect the progress of disease, prognosis helps to identify which tumors are 
more aggressive than others and the possible progression of the tumor [6]. 
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Figure 1.1 Occurrence of different cancers in western countries.  
Although the death rate of cancer is decreasing due to the development of diagnosis 
and therapy, the occurrence of breast and prostate cancers are still increasing. Both of the can-
cers have highest occurrence in the western countries [7] 
 
 
 
1.1.1 Biomarkers and its role in diagnosis, prognosis and treatment  
Molecular targets, which are called biomarkers were discovered by researchers [8]. 
Since cancer is one of the common diseases in the world today, cancer biomarkers are of most 
interests for researchers. An early diagnosis of cancers determines the possibility of curing dis-
ease[9] because the tumor will always prognoses into invasive tumor or metastasis into other 
organs, which makes the therapy even more difficult . Therefore, it is necessary to find a target 
molecule as a biomarker. In order to diagnose or prognoses the cancers accurately and facili-
tate early diagnosis that increases the possibility of curing the cancers,  
3 
Various diagnosis assays have been developed based on the analysis of biomarkers [10]. 
For example, From 1970s, cervix cancer diagnosis by cell sample analysis has been offered. PSA 
(Prostate Specific Antigen) in the urea or blood sample  has been used to be widely applied to 
diagnosing the prostate cancers [11].  
The preferred targets for tumors should be present only in tumor cells and easily recog-
nized by targeting reagents during blood circulation. Therefore, cell surface molecules or struc-
tures in extracellular matrix are suitable for functioning as biomarkers [12]. For example, PSMA 
(Prostate Specific Membrane Antigen) and HER2 are cell membrane proteins which express in 
high level only in specific prostate or breast cancers. 
The perfect target structure for use in tumor targeting should be present only in tumor 
cells, and be easily accessible for targeting agents located in the blood. This makes cell surface 
structures, or structures located in the extracellular matrix, suitable. It is also important that 
the target is available during the whole treatment time, so that the cancer cells do not down 
regulate its expression during treatment. This can be achieved if the target structure is needed 
for the cancer cell to grow and divide. 
Biomarkers have provided valuable information in patient selection. By estimating the 
highest benefit from the treatment, the treatment population can be enriched by biomarkers 
identification. Therefore, biomarkers play important roles in two aspects: first, biomarkers will 
define which patients will benefit from the disease treatment by drugs; second, whether the 
drugs function properly according to the expected mechanism based on biomarkers [13]. In 
nowadays, almost half of the new developed molecular entities are involved in biomarker ele-
ments. 
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 Although biomarkers have been expected to increase the success rates in cancer diag-
nosis and treatments, there are still several challenges in clinical application of biomarkers [14]. 
First, the clearly understanding of biomarkers in the development of cancers is required for the 
clinical process [15]. Second, reliable testing assay of biomarkers is needed for the reproducible 
results. Although PSA is widely used for prostate cancer patient screening, it is not accurate, 
with many false positives that gives wrong information if diagnosis [16]. Third, the detection 
boundaries have to be defined by the constant testing. Fourth, the possible function of a novel 
biomarker during a planned therapeutic strategy has to be estimated before been applied [17]. 
In a summary, all these factors have to be well considered before and during the clinical appli-
cation of biomarkers. 
To be a biomarker, the molecule must possess several properties: it exits in tumor cells 
rather than normal cells; it can be easily detected by targeting agents either in blood or tissue; 
the molecule is available during the treatment period. The cell surface molecules or molecules 
located in extracellular matrix have the highest possibility to be a biomarker. 
In nowadays, almost half of the new molecular entries are involved in the development 
of biomarkers. Targeted prognosis and therapy have increased survival percentage [12]. Design-
ing targeted contrast agents can benefit for the diagnosis and prognosis of diseases.  One sub-
ject of the biomarkers for cancer is receptor on cell surfaces which are widely studied. The pop-
ular receptors like PSA (prostate specific antigen), GRPR (gastrin releasing peptide receptor), 
EGFR (epidermal growth factor receptor) family have been applied clinically for cancer deter-
mination and therapy [18-19]. These receptors always get over expressed in various cancer 
cells. The expression level is also related with the cancer stage [20-21]. Gastrin releasing pep-
5 
tide (GRP) is a member of bombesin like family of which pre-protein is cleaved into GRP of 27 
amino acids or neuromedin C of 10 amino acids [22]. GRP is widely used to conjugate with na-
noparticles, quantum dots or other probes to function as a targeted contrast agent against 
GRPR [19]. Similar as GRP, EGF is the ligand for EGFR, which is the first member of EGFR family 
(Figure 1.2). There is a high expression level of both EGFR and EGF in various cancer cells, like 
breast cancers, ovarian cancers and pancreatic cancers [23]. 
 
Figure 1.2 EGFR family and its targeting molecules 
All the members in EGFR family have an extracellular domain (ECD), a trans-membrane 
domain and an intra-cellular domain. HER2 is the one that does not have a natural ligand for 
the ECD which tends to form dimer with other members. HER3 is the one lack of a kinase do-
main. With some ligand binding in the ECD of either member in the former dimer, the inner ki-
nase pathway may be activated which will promote cell proliferation and agiogenesis.  
 
 
 
 
  
6 
1.1.2 Detection of biomarkers 
Many techniques have been developed to measure specific biomarkers at protein, DNA 
or RNA levels; for example, immunohistochemistry (IHC), enzyme-lined immunosorbent assays 
(ELISA), fluorescent in situ hybridization (FISH) and real time polymerase chain reaction (RT-
PCR), as well as Flowcytometre (Figure 1.3). In order to get reproducible and reliable results 
from the assays, Validation of the methods is critical to the assay [24].  
Take one of the most famous biomarkers for breast cancer, HER2 (human epidermal 
growth factor receptor 2) as an example (Figure 1.2). Since HER2 is involved in signal pathway 
by the intracellular kinase domain. The mutation of the kinase gene will result in poor prognosis. 
Therefore, RT-PCR of the mutated gene can predict the abnormal function of the biomarkers 
[25]. HER2 gene also encodes a trans-membrane protein with the extracellular domain as a tar-
get for antibodies. Several antibodies against HER2 have been developed which makes IHC is 
widely used to measure the expression level of HER2 protein which is related to the disease 
stage. 
However, most of these established methods are invasive by biopsy or surgery.  Unfor-
tunately, the clinical application of targeted therapy is largely limited by current methods for 
assessment of these cancer biomarkers using invasive methods such as biopsy. One of five 
HER2/Neu clinical tests, including biopsy and immunostaining (IHC) provides incorrect results, 
which severely affect the selection of appropriate patients for personalized treatment using 
HER2/EGFR targeted cancer therapies. Limitations of these methods are mainly because of in-
vasiveness. They cannot monitor the tumor in real time. 
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As shown in Figure 1.3, current diagnosis of HER2 is first based on IHC results. IHC will 
predict the expression level of HER2 which is related to the tumor stages. The expression of 
HER2 is generally divided into 4 levels, and only the highest level is suitable for targeted therapy. 
The cancers with lower level of HER2 will need further analysis by FISH to determine the HER2 
gene. However, IHC needs surgery to get the tissue samples for analysis. FISH also need to use 
biopsy to get the tissue sample. These invasive techniques may stimulate the tumor growth and 
metastasis [26]. 
 
 
Figure 1.3 Algorithm for Herceptin use 
In order to diagnose whether the specific type of breast cancer is suitable for Herceptin 
therapy, Cancer tissue samples are required for the diagnostic method of IHC. Only the HER2 
level detected by IHC is up to stage 3, this type of cancer is illegible for Herceptin treatment. If 
the expression level is in stage 2, further diagnosis with FISH to amplify the HER2 DNA will be 
taken to confirm the treatment methods [27]. 
 
 
IHC 
Positive 
3  
Positive 2+ Positive 1+ 
or 0 
Herceptin 
Th  
FISH 
Positive 
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1.2 EGFR family function as biomarkers for diagnosis and therapy 
The epidermal growth factors (EGF) induce signal transduction by activating the kinase 
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and 
survival (Figure 1.2). EGFRs are comprised of four family members: EGFR/HER1, HER2/Neu, 
HER3 and HER4, respectively. They share similar structures with an extracellular ligand binding 
domain, a transmembrane domain, and a functional intracellular tyrosine kinase domain (ex-
cept for HER3). Different from other three receptor family members, HER2/Neu does not have 
a natural ligand and its ECD domain is able to adopt an activated state to dimerize with EGFR or 
HER3 (EGFR/HER2, HER2/HER3). HER2 is the preferred dimerization partner in the EGFR family.  
HER2/Neu and EGFR are also major prognosis biomarkers over-expressed in various types of 
cancer cells [28] and tissue samples from cancer patients [20, 29].  
Various carcinomas, like glioma, bladder carcinomas and lung cancers, have overexpres-
sion of EGFR proteins [30-31]. The EGFR has many ligands, such as EGF and Transforming 
Growth Factor-α(TGF-α). As shown in Figure 1.4, ligand binding cause conformational change 
which exposing the dimerization of domain II. Because of the effects of dimerization, the tyro-
sine kinase sites located in the intracellular domain get phosphorylated. However, Her2 is not 
dependent on the ligand activation. HER2 is the preferred dimerization partner for all the other 
members in the EGFR family. When overexpressed, HER2 homodimers are often formed [32].  
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1.2.1 Structure of EGFR family proteins 
 
Figure 1.4 EGF receptor activation. 
I-IV: domains of the extracellular part of the receptor,  TM: transmembrane domain, IC: 
Intracellular domain. Binding of EGF to the domain one and three of EGFR (HER1) ECD will cause 
the form change of domain and lead to homo-dimerization. 
 
Figure 1.2 shows that the epidermal growth factors (EGF) induce signal transduction by 
activating the kinase domain of the epidermal growth factor receptors (EGFR) to promote cellu-
lar proliferation and survival. EGFRs are comprised of four family members: EGFR/HER1, 
HER2/Neu, HER3 and HER4, respectively. 
They share similar structures with an extracellular ligand binding domain, a transmem-
brane domain, and a functional intracellular tyrosine kinase domain (except for HER3). The 
EGFR has many ligands, such as EGF and Transforming Growth Factor-α(TGF-α). As shown in 
Figure 1.4, ligand binding cause conformational change which exposing the dimerization of do-
main II. Because of the effects of dimerization, the tyrosine kinase sites located in the intracel-
lular domain get [33] .   
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Different from other three receptor family members, HER2/Neu does not have a natural 
ligand. HER2 is the preferred dimerization partner for all the other members in the EGFR family. 
When overexpressed, HER2 homodimers are often formed [34-35]. Its ECD domain is able to 
adopt an activated state to dimerize with EGFR or HER3 (EGFR/HER2, HER2/HER3). Among the 
EGFR members, HER2 is the one which is lack of natural ligand for the extracellular domain. 
Therefore, HER2 has to form dimer with other family members to activate the downstream sig-
nal pathway [36]. Since HER3 is lack of the tyrosine kinase domain, when HER2 and HER3 form 
into a heterodimer, binding of the ligand to HER3 will activate the tyrosine kinase function of 
HER2. Various antibodies or other peptides have been developed to target to HER2 (Figure1.5). 
To date, there are structures of extracellular domains have been determined mainly by X-ray 
crystallography [37]. As shown in Figure 1.5, these structures reveal a fixed conformation for 
HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB 
receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region 
of HER2, identifying this site as a target for anticancer therapies [37]. This binding may facilitate 
the endocytosis by providing direct interaction of the formed steric barrier to the transmem-
brane regions [38]. By identify the binding patterns of Herceptin Fab domain and HER2 ECD,  a 
basis of designing new targets for HER2 has been generated for diagnosis and therapeutic ef-
fects. 
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Figure 1.5 Crystal structure of HER2 and HER2-Herceptin complex 
The Fab domain of antibody Herceptin targets to the domain 4 of HER2 ECD close to the 
transmembrane domain. This may facilitate the endocytosis of HER2 after binding with Hercep-
tin. The ADCC (antibody dependent cytoxicity) will be triggered after binding [37]. 
 
 
1.2.2 Roles of EGFR family in tumor formation and growth 
As epidermal growth factor receptors, HER family proteins express on the cell mem-
brane. Both of the transmembrane proteins are important in tissue normal growth and devel-
opment [39].  The expression level of EGFR is relatively low in normal tissues except normal skin 
epithelial cells. EGFR is also widely expressed in the tumor epithelial cells [40-41]. The expres-
sion level of HER2 is about 103-104 per normal cell; however, the expression is up to 106 per cell 
in cancer cells especially in breast cancers. 
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A  
B  
Figure 1.6 EGFR (A) and HER2(B) are negative prognostic factors in breast cancers 
Those biomarkers that indicate lower survival rate are called negative prognostic bio-
markers. Those cancer cells with higher expression level of EGFR or HER2 will have relatively 
lower survival rate and shorter survival time [42-43].  
 
EGFR family members play an important role in various tumor etiology including breast 
cancers, ovarian cancers, pancreatic cancers, prostate cancers and lung cancers (Figure 1.6). 
The over expression of EGFR proteins as a consequence of amplification of EGFR genes in can-
cer cells is involved in tumor matastasis and aggressiveness. The reason of the over expression 
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of EGFR proteins is due to the character of EGFR as they can cause the loss of tumor suppres-
sion gene because EGFR is mutationally activated in half of the cancer cells [41].  
Among of the members, HER1 and HER2 are two well established biomarkers for diag-
nosis and treatments. About 30% of the breast cancers have over expression of HER1 or HER2. 
HER1 over-expresses in many solid tumors. By binding with its ligands, a signaling network will 
be triggered (Figure 1.2). The tyrosine kinase domain will be activated for the downstream sig-
nal path way [1, 44]. Therefore, the cell proliferation and angiogenesis will be promoted and 
the cell apoptosis will be inhibited [1]. The HER2 positive breast cancer is correlated with high 
matastasis and low survival rate.  HER2/Neu and EGFR are also major prognosis biomarkers 
over-expressed in various types of cancer cells [28] and tissue samples from cancer patients 
[20, 29]. Various carcinomas, like glioma, bladder carcinomas and lung cancers, have overex-
pression of EGFR proteins [30-31]. Table 1 shows that up to 69% percentage of tumors have 
high expression level of EGFR especially in later stage. Table 2 shows HER2 has high expression 
level in about 30% tumor cells. However, HER2 expression is also over expressed in the early 
stages of these cancers, which will benefit for the early diagnosis [45]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
 
 
Table 1 EGFR overexpression rate in different stages of cancers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source N
Definition of 
HER1/EGFR 
overexpression/EGFR
amplification
Percentage of tumors 
overexpressing HER1/EGFR
Onn et al, Clin 
Cancer Res, 
2004
111 2 or 3 staining by IHC 60%
Rusch et al, 
Cancer Res, 
1993
44 Increase detection by 
Northern analysis
45%
Selvaggi et al, 
Ann Oncol, 2004
48 2+ or 3+ staining by IHC 37%
Ohtsuka et al, J 
Thorac Oncol, 
2006
48 2+ or + by Western 
blotting
40%
Dancer et al, 
Oncol Rep, 
2007
32 Two-fold or greater 
amplification of the EGFR
gene by FISH 
65%
Bloomston et al, 
Dig Surg, 2006
71 1+ or higher staining 
by IHC 
69%
Thybusch-
Bernhardt et al, 
Int J Surg
Investig, 2001
24 Positive staining 
by IHC 
33%
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Table 2 HER2 overexpression rate in different stages of cancers 
 
 
 
The over expression of EGFR and EGFR2 are associated with poor prognosis (Figure 1.6) 
[10, 46]. The epidermal growth factors (EGF) induce signal transduction by activating the kinase 
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and 
survival (Figure 1.2). HER2/Neu and EGFR are over-expressed in various types of cancer cells 
[28] and tissue samples from cancer patients. HER2 is a negative prognostic factor [20, 29]. In 
numerous clinical studies, it is reported to associate with shorter disease-free and overall sur-
vival for breast and ovarian cancers as well as increased risk of death. About 30% of all breast 
cancer cases are associated with expression of HER2/Neu. High expression of HER2/Neu closely 
correlates with low survival rate [45, 47-48]. The rate of HER2/Neu overexpression was esti-
mated within a wide range of 6-35% in gastric cancer [49], 9-32% in ovarian cancer [50], and  in 
up to 70% of human pancreatic cancer [51]. EGFR also leads to increased cell proliferation and 
Source N 
Definition of HER2 
overexpression/HER2 
amplification 
Percentage of tumors with 
HER2 overexpression/HER2
amplification 
Slamon et al, 
Science, 1987
189 Two-fold or greater 
amplification of HER2 gene 
by Southern blot 
30%
Paik et al, 
J Natl Cancer 
Inst, 2000
2034 Definite membrane staining 
by IHC in any tumor cell 
29%
Owens et al, 
Clin Breast 
Cancer, 2004
16,092
(FISH)
116,73
6 (IHC) 
Two-fold or greater 
amplification of HER2 gene 
by FISH
2+ or higher result by IHC 
23%
20% 
Seshadri et al, 
J Clin Oncol, 
19934
1056 Two-fold or greater 
amplification of HER2 gene 
by slot blot 
21%
Andrulis et al, 
J Clin Oncol, 
1998
580 Two-fold or greater 
amplification of HER2 gene 
by Southern blot, slot blot, 
and/or RT-PCR 
20%
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motility and decreased apoptosis [52]. EGFR is also a negative prognostic factor for multiple 
tumor types, including non-small cell lung carcinoma (NSCLC) and pancreatic cancer [53]. 
Co-expression of EGFR and HER2 is found in 10–36% primary human breast carcinomas, 
and it is generally associated with a poor prognosis compared with expression of a single recep-
tor [34, 54-56]. To date, the roles of EGFR and HER2/Neu in the progression of pre-invasive duc-
tal carcinoma in situ (DCIS) to potentially lethal invasive breast cancer remain under hot debate. 
HER2/Neu is overexpressed in 60 to 70% of DCIS tissues which is much greater than in invasive 
breast cancer tissues (~30%). In contrast, overexpression of HER2/neu is not found in normal 
ductal cells or in hyperplasic ductal cells [57]. In addition, it has been shown that 14 to 91% of 
human breast carcinomas express a high level of the EGFRs [52]. The majority (70%) of DCIS tis-
sues identified by mammographic microcalcification are of high grade comedo type, which is 
associated with a high proliferation rate, lack of estrogen receptor, and high expression  levels 
of EGFR and HER2/neu [53].  The importance of EGFR signaling in the growth of DCIS tissues is 
further supported by study results obtained from examination of the effects of an EGFR inhibi-
tor, iressa, on human DCIS tissues xenografted in nude mice [58-59].   
 
1.2.3 Distribution of EGFR family members in various cancers and cell lines 
There are more than 20 cell lines which have high expression level of HER2. They mainly 
come from breast tumor, ovarian and pancreatic tumors. Among these cell lines, several pairs 
of positive and negative HER2 cell lines are widely used in research (Table 3) [9]. 
SKBR-3 is one of the most traditional human breast cancer cell lines. This cell line was 
derived in 1970 from pleural effusion cells. AU-565 was established from the same patient as 
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SKBR-3. The AU565 cell line amplifies and overexpresses the HER2 oncogene; it expresses the 
HER-3, HER-4 and p53 oncogenes. The expression level of HER2 in AU565 is much higher than in 
SKBR-3. These two cell line are usually used to study the effect of drug or protein to HER2 cell 
lines. However, their tumorigenicity is very low. As a result of that, they are not proper for a 
tumor mouse model. 
 SKOV-3 cell line is a hypodiploid human cell line which originated from ovarain cancer. 
The Her2 expression level is higher than SKBR-3. It can generate tumor in nude mice with well 
differentiated adenocarcinoma. Because of its ability to generate well shaped tumors, it is 
widely used on nude mouse for Her2 tumor model. Compare with SKOV-3, BT474 is another cell 
line which is also commonly been used for generating tumors. BT-474 was isolated by E. Lasfar-
gues and W.G. Coutinho from a solid, invasive ductal carcinoma of the breast. The expression 
level of BT474 is similar as AU565. Besides these genital cancers, pancreatic cancer sometime 
also has a high expression level of Her2, such as MIAPaca-2. 
 
Figure 1.7 HER2 expression level of various cancer cells 
The HER2 expression levels have been measured in different cell lines. The cell line 
SKOV-3, SKBR-3 and BT474 with an expression level up to 106 per cell are called HER2 positive 
cell lines. The cell lines with expression level less than 104 are called HER2 negative cell lines. 
0.00 1.00 2.00
BT474
SKBR3
SKOV3
MCF7
MDA-MB-231
MDA-MB-361
×106
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Based on the choice of positive cell lines, negative cell lines can be decided as a pair. For 
example, MCF-7 and MDA-MB-231 come from breast cancer which can be control for SKBR-3 
and AU565 (Table 3). By choosing cell lines from similar sources, the species difference can be 
minimized. 
Mouse EGFR-2 is different from HER2 which are from human. However, mouse EGFR-2 
is also related to breast cancer of mouse. Both NT5 and EMT-6 are form mouse mammary can-
cer; EGFR-2 is overexpressed in NT5.  
 
1.3 Targeted reagents for EGFR family 
Besides the endogenous ligands for EGFR members, various targeted reagents, like anti-
bodies and peptides, have been developed against EGFR members. Based on the targeted re-
gion of the receptor, the targeted reagents can be generally divided into two types. One type of 
reagents targets to the intracellular domain of EGFR; while another type targets to the extracel-
lular domain of EGFR [2, 60]. The intracellular targeting reagents are inhibitors to the tyrosine 
kinase domain. The reagents target to the extracellular domain can cause endocytosis, ADCC 
(antibody dependent cytoxicity) effects of the cancer cells. The targeted molecules can be anti-
bodies such as, Herceptin, protein domain such as EGF and affibody, peptide, such as Latibnib 
and small molecules such as Taxol [61]. The traditional cancer treatment like radiation therapy 
and chemotherapy, will affect all normal cells. To use protein as a drug, it will decrease the tox-
icity and increase the specificity. 
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The drugs are summarized in Table 4 [62]. Small molecules like Lapatinib function as the 
kinase domain inhibitor can inhibit both EGFR and HER2. The HER2 specific antibody like Trastu-
zumab (Herceptin) only target to the extracellular domain of HER2 which can inhibitor the HER2 
expression specifically.  
Table 3 HER2 inhibitor in clinical use [63] 
 
Drug Type Target Source Current clinical status 
Monoclonal antibodies 
Pertuzumab Humanized HER2 
Genen-
thech/Roche 
Phase II trials in breast and ova-
rian cancer with other reagent 
Trastuzumab Humanized HER2 
Genen-
thech/Roche 
Lanched for breast cancer in 
combination with chemo thera-
py 
Tyrosine kinase inhibitors 
Lapatinib Thioquinazoline HER1/HER2 
GlaxoSmith 
Kline 
Lanched for second-line breast 
cancer treatment in combination 
with capecitabine 
EKB-569 Cyanoquinoline HER1/HER2 Wyeth 
Phase II trials in colorectal and 
non-small cell lung cancers 
BIBW-2992 Quinazoline HER1/HER2 
Boehringer 
Ingelheim 
Phase II trials in breast, non-
small cell lung  and head cancers  
Neratinib Cyanoquinoline Pan-HER Wyeth 
Phase II trials in breast and non-
small cell lung cancers 
AEE-788 
Pyrrolopyrimi-
dine 
HER1/HER2 Novartis Phase I/II 
ARRY-543 Quinazoline HER1/HER2 
Array Bio-
phama 
Phase I 
BMS-599626 Pyrrolotriazine Pan-HER 
Bristol-
Myers 
Squibb 
Phase I 
 
1.3.1 Intra-cellular inhibitor an extra-cellular ligands of EGFR (HER1) 
The epidermal growth factor receptors EGFR and HER2/Neu are highly expressed as 
biomarkers in various cancers and play important roles in cancer progression and survival. They 
are also the major drug targets. Several targeted drugs such as monoclonal antibodies (Hercep-
20 
tin or Trastuzumab) and small inhibitors (Erlotinib) against HER2 and EGFR have been shown to 
be effective with patients over-expressing those biomarkers. Unfortunately, the clinical applica-
tion of targeted therapy is largely limited by current methods for assessment of these cancer 
biomarkers using invasive methods such as biopsy. One of five HER2/Neu clinical tests, includ-
ing biopsy and immunostaining (IHC) provides incorrect results, which severely affect the selec-
tion of appropriate patients for personalized treatment using HER2/EGFR targeted cancer ther-
apies [34, 64]. 
The epidermal growth factors (EGF) induce signal transduction by activating the kinase 
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and 
survival (Figure 1.3). HER2/Neu and EGFR are over-expressed in various types of cancer cells 
[28] and tissue samples from cancer patients. HER2 is a negative prognostic factor [20, 29]. In 
numerous clinical studies, it is reported to associate with shorter disease-free and overall sur-
vival for breast and ovarian cancers as well as increased risk of death. About 30% of all breast 
cancer cases are associated with expression of HER2/Neu. High expression of HER2/Neu closely 
correlates with low survival rate [45, 47-48]. The rate of HER2/Neu overexpression was esti-
mated within a wide range of 6-35% in gastric cancer [49], 9-32% in ovarian cancer [50], and  in 
up to 70% of human pancreatic cancer [51]. EGFR also leads to increased cell proliferation and 
motility and decreased apoptosis [52]. EGFR is also a negative prognostic factor for multiple 
tumor types, including non-small cell lung carcinoma (NSCLC) and pancreatic cancer [53]. 
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1.3.2 Engineered antibodies and drugs for HER2 
Based on the function as biomarkers of HER2 and EGFR, especially HER2 without a natu-
ral ligand, a lot of antibodies haven been developed against HER2. Antibodies have therapeutic 
function by several pathways. Because HER2 mediates cell signaling pathways such as PI3K and 
MAPK (mitogen activated protein kinase) pathways, antibody targeting to HER2 can cause ADCC 
effects which make the cancer cells been swallowed by macro cells [65]. At the same time, an-
tibody can inhibit proteolysis of HER2 ECD and inhibition the HER2 DNA repair [35].Regarding 
these mechanisms, antibody resistance is also developed by loss of antibody binding, increased 
downstream signaling and activation of alternative growth factor pathways. 
As shown in Figure 1.3 and Table 3, several targeted drugs such as monoclonal antibo-
dies (Herceptin or Trastuzumab) have been developed to against the ECD domain (which re-
gion) of the  epidermal growth factor receptors EGFR and HER2/Neu expressed at the cell sur-
faces of  various cancers [66-67]. Based on the function as biomarkers of HER2 and EGFR, espe-
cially HER2 without a natural ligand, a lot of antibodies haven been developed against HER2 
(Table 4).  
Because HER2 mediates cell signaling pathways such as PI3K and MAPK (mitogen acti-
vated protein kinase) pathways, antibody targeting to HER2 can cause ADCC effects which make 
the cancer cells been swallowed by macro cells [65]. At the same time, antibody can inhibit pro-
teolysis of HER2 ECD and inhibition the HER2 DNA repair [35].Regarding these mechanisms, an-
tibody resistance is also developed by loss of antibody binding, increased downstream signaling 
and activation of alternative growth factor pathways. 
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Due to antibody resistance, other techniques for curing cancer cell through antibodies 
are shown in Figure 1.8. The Fc domains of antibodies have been conjugated with drugs, toxic 
proteins, radioisotopes and thermotherapy drugs. 
 
 
Figure 1.8 Therapeutic effects through antibodies 
For antibodies been used as therapeutic reagents, they may kill the cancer cells or get 
cancer cells apoptosis in different mechanisms [68]. (A) ADCC effects will be triggered by anti-
body that helps the macro cells to swallow cancer cells. (B) The antibody is conjugated with 
some predrugs which function as a drug once gets into cytosol by killing the cancer cells. (C) 
Some toxic proteins which binds to antibody non-covalently will be released in the cytosol and 
inhibit the cell growth. (D) For those radioactive labeled antibody, the radioactive reagents will 
break the DNA replication of cancer cells directly. (E) The antibody can also be conjugated with 
some clinically available chemotherapy medicine. Antibody will provide the specific targeting 
and help the chemotherapy medicine to locate in the cancer area which will eliminate the 
harmful effects to normal cells. 
 
 
 
A B C D E
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1.4 Affibody library and screening 
Affibody was selected as our targeted sequence because the suitable size for molecular 
imaging of moderate circulation time [69].  Affibody is originated from the “z” domain of pro-
tein A, which contains 58 amino acids (Figure 2.1). A variant of this affibody called ZHER342 can 
specifically target to HER2 with the Kd of 22 pM. Because of its small molecular weight (7 KDa), 
there are more advantages than antibodies for the affibody to penetrate deeper tissue and tar-
get the HER2 positive sites. Affibody is able to penetrate the blood vessel and well distribution 
in the tumor mass. Biodistribution in SKOV-3 xenografts indicates that the up-take of reagent in 
tumor sites by affibody targeting [70-71]. 
 
1.4.1 Affibody derived from z-domain of Protein A and screened by phage display 
Affibody is originates from the “z” domain of protein A, which contains 58 amino acids. 
Affibody molecules with affinity for HER-2 were selected using phage display. The produced af-
fibody molecules were tested for binding to HER-2 ECD immobilized to a Biacore sensorchip.  
Three generations of affibody for HER2 were developed.  ZHER2-4 is the first generation of affibo-
dy with 13 mutations at domain 1 and 2 (Figure 1-9).  It has a Kd for HER2 of 50 nM [72]. A va-
riant of the second generation affibody called ZHER2:342 has 7 mutations at L9M, Q11N, Q17A, 
A18L, W24N, T25Q and S26K from previous generation, which has a Kd for HER2 about 22 pM 
(Figure 1-9) [73]. EGFR affibody call ZEGFR:1907 was screened from affibody library by extracellular 
domain of EGFR which has a Kd of 43.6 nM for EGFR [74]. 
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Figure 1.9 Structure and Sequences alignment of affibody 
Affibody is a phage display library with 13 amino acids in domain 1 and domain 2 to be 
random. Different affibody variants are screened by specific antigen like HER2 or EGFR. ZHER2:4 is 
the first generation of affibody against HER2 and ZHER2:342 is the secondary generation which in-
crease the binding affinity by changing the Kd from 50 nM to 22 pM. ZEGFR:1907 is a variant specif-
ic targets to EGFR. 
 
There are several advantages for the affibody than antibodies as a Her2 targeting moie-
ty. First, it can be quickly diffused in vivo and then target to the biomarkers. Second, the opti-
mized size enables affibody to penetrate cell membrane for endocytosis. The endocytosis al-
lows enough affibody molecules concentrate at the cancer cells, which fulfills the molecular im-
aging of biomarkers. Third, affibody can also be secreted out of the body in shorter time than 
antibodies, which will minimize the toxicity.  The radioactively labeled affibody was injected in-
to nude mice with SKOV-3 tumor model. Affibody can specifically target to the tumor in 24 hr 
[75]. Figure 1.10 shows that HER2 affibody ZHER2:342 can bind to cells with high expression level 
of HER2 and has the endocytosis effects [69]. As a targeting moiety, affibody has several advan-
tages. First, it is relatively stable in vivo compared with peptide fragments.  Second, HER2 affi-
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body is able to penetrate deeper tissue. Third, Biodistribution in SKOV-3 xenografts indicates 
the up-take of reagent in tumor sites by affibody targeting. 
 
Figure 1.10 ZHER2:342 is endocytosed into SKBR-3 cancer cells with HER2 over expression. 
HER2 is a protein on the cell membrane. The cells were stained with fluorescent 
(Fluo555 with excitation wavelength at 555 nm) conjugated affibody ZHER2:342. Staining in the 
cell plasma indicates that the ZHER2:342 gets inside of the cancer cells. 
 
 
1.4.2 ZEGFR:1907 binds to EGFR with highest affinity 
Affibody molecules specific for the epidermal growth factor receptor (EGFR) have also 
been selected by phage display technology from a combinatorial protein library based on the 
58-residue, protein A-derived Z domain. Three selected Affibody variants were shown to selec-
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tively bind to the extracellular domain of EGFR (EGFR-ECD). Kinetic biosensor analysis revealed 
that the three monomeric Affibody molecules bound with similar affinity, ranging from 130 to 
185 nM. Head-to-tail dimers of the Affibody molecules were compared for their binding to re-
combinant EGFR-ECD in biosensor analysis and in human epithelial cancer A431 cells. Although 
the dimeric Affibody variants were found to bind in a range of 25–50 nM affinities in biosensor 
analysis, they were found to be low nanomolar binders in the cellular assays. Competition as-
says using radiolabeled Affibody dimmers confirmed specific EGFR-binding and demonstrated 
that the three Affibody molecules competed for the same epitope. Immunofluorescence micro-
scopy demonstrated that the selected Affibody dimers were initially binding to EGFR at the cell 
surface of A431, and confocal microscopy analysis showed that the Affibody dimmers could 
thereafter be internalized.  
 
1.5 Clinical imaging techniques and the application 
Visualization techniques are widely used to determine the exact location of the tumors 
before surgery, and also to determine if metastasis is present and to monitor the tumor burden 
during therapy. The most widely used imaging techniques include: MRI (Magnetic Resonance 
Image), PET (Positron emission tomography), Ultra sound, GFP (Green Fluorescent Proteins), 
NIR (Near infra-red) in animals and other radioactive methods.  
Based on the function and mechanism, these imaging methods can be classified as two 
categories [76]. One is an optical image to detect inner but lower imaging, like NIR and fluores-
cence, has relatively high sensitivity but low resolution. The penetration depth also limits the 
application of optical images [77]. The other one is spectrum image, like MRI and PET. Most of 
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the optical image techniques have the limitation in depth. The imaging signal varies due to the 
depth change in vivo. Spectrum image techniques are able to show much deeper penetration 
(Figure 1-10). However, the spectrum technique like PET using radio isotopes to create radioac-
tive signals, have disadvantages in harmful components. 
1.5.1 Magnetic Resonance Imaging and its application 
Magnetic resonance imaging (MRI) is one of the most powerful imaging techniques in 
preclinical and clinical diagnosis due to its significant advantages in non-invasiveness and no 
restrictive limitations [78]. MRI measures the water hydrogen properties and interactions in an 
external magnetic field. MRI is able to detect signals in tissues from 1 mm to 1 m in thickness. 
The high resolution to distinguish various organs also makes MRI a possible technique in clinical 
application [79].   Since the MRI signals are from water molecules, the soft tissue such as brain 
tissue, which contains high amount of water, will demonstrate strong MRI signals called func-
tional MRI (fMRI). Functional MRI is based on the increase in blood flow to the local vasculature 
that accompanies neural activity in the brain. The hemodynamic response from fMRI is related 
to neural activities, so fMRI is widely used in neuroimaging [80-81]. For example, the brain tu-
mor is easier to be identified by identifying the change of brain structure using fMRI. For other 
organs especially tumors, their detections are hindered by the low sensitivity and signal to 
noise ratio of MRI. Due to the lower proton density, regular tissues demonstrate relatively low-
er signals in the magnetic field comparing with soft tissues.  In order to make MRI suitable for 
various diseases, contrast agent is required for MRI to image different organs except for the 
brain tissue. About 1/3 of MRI scanning requires the use of MRI contrast agents [82]. 
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1.5.2 Near Infra-red imaging and in vivo application 
Near Infra-red (NIR) imaging is one type of the optical imaging, which detects the 
transmission protons, penetrates through the tissue since short wavelength of the red color 
enables it transparent of tissues [83]. The emission wavelength of NIR is between 700-1000 nm 
[76]. Like all the other optical imaging, the photon transmission from tissue is largely affected 
by tissue absorption and scattering. NIR dye can be used for in vivo imaging mainly because of 
three advantages. First, NIR imaging has a high sensitivity even in nano molar level of molecules 
[84], which benefits a molecular imaging for biomarkers. Second, animal body has relatively low 
background fluorescence in near infrared region. Third, compared to other fluorescent dyes like 
green fluorescence, NIR imaging has better penetration capability. This enables non-invasive 
imaging by NIR dyes.  
However, several limitations still hinder the application of NIR imaging in animals. First, 
most NIR dyes are organic compounds with a molecular weight less than 1.2 KDa [85]. Since 
these small molecules have relatively short circulation time in animal bodies, they are conju-
gated to large molecules like nano-particles and proteins for in vivo imaging [86-87]. The distri-
bution and pharmacokinetics of NIR dyes have been perturbed by the conjugated molecules. 
Second, in order to increase the signal to noise ratio (SNR), a filtration wavelength needs to be 
appropriately selected to minimize the auto-fluorescence [76]. Besides, low toxicity and mole-
cular stability are also required for the NIR dyes. This problem has been solved by molecular 
modification and conjugation [88]. 
Although NIR dye has high sensitivity and the intensity is linear to the dye concentration, 
which is important for the quantitative analysis in the research, the low resolution makes it dif-
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ficult to distinguish different organs. In a summary, NIR imaging performs is very efficient in 
probing the drugs or biomarkers; however, due to low resolution it is not suitable for further 
studying tissue structure as well as prognosis.  
 
1.5.3 Other techniques of molecular imaging 
The X-ray technique, a 3 dimensional X-ray imaging tool, is used in mammography for 
solid organs like bones and CT; however it uses gamma-camera which is radioactive and inva-
sive. 
Positron-emission tomography (PET) technology is also commonly used for the clinical 
diagnosis. PET is an image generated from radionuclides (tracer). This trace can emit pairs of 
gamma rays which will be detected by the PET system and generated as a three dimensional 
image [89]. In modern scanners, the PET and CT are combined to demonstrate a comprehensive 
image of a whole living body. PET can image the soft tissue, while the CT scans the solid organ 
as bones by X-ray.   Both PET and CT have been used for many years in clinical diagnosis be-
cause of their high sensitivity and availability [75]. However, the PET imaging is based on the 
decay of radioisotopes, which is harmful. Those isotopes with shorter half life times were se-
lected, including: 11C, 13N, 18F, 64Cu, 68Ga, and so on [90]. Short half life time requires a sensitive 
detector in the PET system or high amount of the tracers to generate an image with enough 
resolution. 
A tumor tracing molecule, coupled to a suitable radionuclide (gamma-emitting for use in 
the gammacamera or positron-emitting for use in PET) is administrated, and when the tracer 
has reached the tumor, images are taken. The most used PET-tracer is FDG - a 18F labeled glu-
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cose molecule that visualizes areas with high metabolism, such as tumor and inflammation 
areas. 
Molecular imaging assists the research, diagnosis or therapy of diseases on a molecular 
level. This requires a series of biomarkers for various diseases and a necessary carrier to facili-
tate imaging reagents recognizing the biomarkers. Quantum dot is one of the best carriers for 
the molecular imaging. Quantum dot was first introduced to the fluorescent imaging area; be-
cause it solves several problems for the organic fluorophores [88]. The inorganic core and shell 
will narrow the emission range of the fluorophores within 25-35 nm. The background will dra-
matically decrease in such a narrow range [88]. 
 
1.6 Molecular imaging 
Molecular imaging differs from traditional imaging in that probes known as biomarkers 
are used to help image particular targets or pathways. Molecular imaging is a prospective tech-
nique in various areas like life science, physical science and neurology. Most diseases involve a 
molecular basis; therefore, molecular imaging will facilitate the prognosis and diagnosis. It is 
also expected to be applied in monitoring drug treatment via imaging biomarkers [56, 76, 91]. 
The most widely used imaging techniques include: MRI (Magnetic Resonance Image), PET (Posi-
tron emission tomography), Ultra sound, GFP (Green Fluorescent Proteins), NIR (Near infra-red) 
in animals and other radioactive methods. They can be classified as two categories [76]. One is 
optical image to detect inner but lower imaging, like NIR and fluorescence. Optical image has 
relatively high sensitivity but low resolution. The penetration depth also limits the application 
of optical images [77]. The other one is spectrum image, like MRI and PET. Most of the optical 
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image techniques have the limitation in depth. The imaging signal varies due to the depth 
change in vivo. Spectrum image techniques are able to show much deeper penetrations (Figure 
1.11). However, the spectrum technique like PET using radio isotopes to create radioactive sig-
nal, have disadvantages either in harmful components. 
Since nowadays, molecular imaging is not only used for studying basic biological 
process, but also used for understanding the mechanism of disease development in molecular 
level, it is expected that the molecular imaging will provide better differentiations in prognosis, 
diagnosis and monitoring therapies by using various biomarkers [92]. 
Molecular imaging assists the research, diagnosis or therapy of diseases on a molecular 
level. This requires a series of biomarkers for various diseases and a necessary carrier to facili-
tate imaging reagents recognizing the biomarkers. 
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Figure 1.11 Spatial resolution and penetration depth of molecular imaging techniques 
The x-axis indicates the spatial resolution of different imaging techniques. The y-axis 
shows the sensitivity in (A) and penetration depth in (B). MRI has the largest spatial resolution 
comparing with other techniques; however, its sensitivity is very low. 
 
 
A
B
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1.7 Contrast agents for molecular imaging 
Contrast agents in molecular imaging are those reagents which can enhance the signal 
of imaging or distinguish the disease organs and non-disease organs [93].  
In NIR imaging, NIR dye itself function as a contrast agent. Quantum dot is one of the 
popular carriers for the molecular imaging. Quantum dot was first introduced to the fluorescent 
imaging area; because it solves several problems for the organic fluorophores [88]. The inorgan-
ic core and shell will narrow the emission range of the fluorophores within 25-35 nm. The back-
ground will dramatically decrease in such a narrow range [88]. 
Contrast agents in MRI field are more widely used because MRI has high resolution but 
low sensitivity. To enhance the sensitivity of imaging, 35% of MRI scans utilize the injection of 
MRI contrast agents with paramagnetic, ferromagnetic or super paramagnetic metal ions. In 
this dissertation study, we will focus on developing MRI contrast agents. 
 
1.7.1 MRI contrast agents 
MRI contrast agents are used to shorten the relaxation time (T1 and T2) of the protons 
in the tissue area [82]. Based on the mechanisms, MRI contrast agents can be divided into two 
categories: contrast agents which enhance the same level of longitudinal and transverse relaxa-
tion are called T1-weighted contrast agents. Contrast agents with much longer transverse re-
laxation than longitudinal relaxation is called T2-weighted contrast agents [94]. The most com-
mon T1 weighted contrast agents are gadolinium (Gd3+) based, since Gd3+ is a lanthanide metal 
with seven unpaired electrons, high magnetic moment, and long electron spin relaxation time 
[95]. Most iron based contrast agents are T2 weighted. For Gadolinium based contrast agents, 
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Gd3+ perturbs the surrounded proton relaxivity. In order to increase the exchanged water num-
bers with Gd3+ and prevent the toxicity of Gd3+, an encapsulated chelator is required, such as 
Gd-DTPA and Gd-DOTA [96].  
Gadolinium, Gd3+, a lanthanide metal with seven unpaired electrons, high magnetic 
moment, and long electron spin relaxation time, is one of the most widely used ions in T1-
weighted MRI contrast agents [97]. Since free Gd3+ is highly toxic with LD50=0.2 mmol/kg in 
mice [96], it must be encapsulated by chelators. Current FDA approved MRI contrast agents are 
based on small chelators (Table 4). Unfortunately, these clinical contrast agents only have a re-
laxivity of about 5 mM-1 s-1. For example, Gd-DTPA, has a r1 relaxivity of 3.8 mM-1 s-1 at 20 
MHz.[94, 98] In order to detect contrast changes due to the difference of proton relaxation 
time in organs clinically, a relaxation rate change of 0.5 s-1 is required [82]. Thus, a local concen-
tration of 100 μM of contrast agent is required [82, 99].  In general, about 0.1-0.3 mM/ kg injec-
tion dose is needed to obtain high contrast in human and small animal tissues.  
             The high concentration of contrast agent required for contrast is indicative of low effi-
ciency and results in increased risk for certain disorders. Nephrogenic systemic fibrosis (NSF), a 
disease found in patients with kidney disease, has been correlated with the use of a gadoli-
nium-based MRI contrast agents and is reported to be related to the release of free Gd3+[100-
103]. Further, small molecular contrast agents have a very short half life time (half-life around 
0.5-3 min in the blood vessels of mice and elimination half-life about 1.5 hours in patients [104-
105]) that limits the time window for MRI data collection and often requires repeated dose in-
jections. Moreover, such local concentration and detection limits (~30 µM in mouse skeletal 
muscle for the contrast agent [Gd(HP-DO3A)(H2O)][106]) further hinder the number of poten-
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tial biological targets for molecular imaging. Therefore, there is an urgent need to develop con-
trast agents with significantly improved relaxivity, optimal retention time, and potential target-
ing capabilities. 
 
Figure 1.12 Model structure of ProCA1-CD2 
Protein based contrast agents are designed by grafting a metal binding site in the stable 
protein like CD2. For MRI contrast agents, Gd3+ binding site was designed. 
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Table 4. Physicochemical characteristics of commercially-available, extracellular, pre-
dominantly renally excreted gadolinium-based MR contrast agents. 
 
 
1.7.2 Biomarkers targeted contrast agents 
In order to view by MRI, the local concentration of contrast agents should be up to mi-
cro molar level [107]. By concentrating the contrast agents in the tumor area is required for im-
aging the tumor tissue. As discussed in previous chapters, biomarkers are expressed endoge-
nously and can be detected as an indicator of biological status. Normally, a biomarker will have 
at least two characteristics: first, the biomarker can be probed by contrast agents for molecular 
imaging; second, the biomarker is sensitive to drugs or medicine for targeted therapeutics [14]. 
To generate imaging on biomarkers has benefitted the selection of drug treatments. Therefore, 
designing contrast agents to target to biomarkers is essential for the clinical diagnosis and ther-
apy. 
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(Eovist) 
Vasovist   
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BMA 
Gd-BOBTA Gadobutrol Gadoversetamide Gd-EOB-DTPA gadofosveset 
trisodium 
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company Bayer Schering 
Pharma 
Guerbet Bracco GE Healthcare Bracco Bayer Schering 
Pharma 
Tyco Bayer Schering 
Pharma 
Bayer 
Schering 
Pharma 
 
 
 
  
 
Year of first 
approval 
1988 1994 1992 1993 2004 2000 1999 2004 inEurope; 
2007 in Japan; 
2008 in US 
   
Molecular 
structure 
Linear, ionic Cyclic, ionic Cyclic, 
nonionic 
Linear, 
nonionic 
Linear, ionic Cyclic, nonionic Linear, nonionic Linear, ionic Linear, ionic    
Thermodynamic 
Stability constant 
(log Keq) 
22.11 
22.57 
25.81 23.81 16.91 22.61 21.81 16.61 23.461 N/A   
Conditional 
stability constant 
at pH 7.4 
18.12 
18.47 
19.02 17.12 14.92 18.42 N/A2 15.02 N/A2 
18.77 
N/A2   
Acid dissociation 
half life in 0.1N 
HCl 
10 min2 > 1 month2 3 hours2 35 second2 N/A2 N/A2 N/A2 N/A2 N/A2   
Osmolality 
(Osm/kg) 
1.961 1.351 0.631 0.651 1.971 1.61 1.111 0.6881 0.7-0.953   
Viscosity (mPa.s 
at 37℃) 
2.91 2.01 1.31 1.41 5.31 4.961 2.01     
T1 relaxivity 
(L/mmol.s-1) 
1.5T, plasma 
4.14 3.64 4.14 4.34 8.34 4.74 4.74     
T1 relaxivity 
(L/mmol.s-1) 3T, 
plasma 
3.74 3.54 3.74 4.04 6.24 3.6 4.54     
Metal chelate 
(mg/ml) 
4694 278.34 279.34 2874 3344 6054 330.94     
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As discussed in the Chapter 1.1, most of the receptors have their ligands, the ligands 
themselves can be used as targeted reagents for contrast agents.  
 
1.7.3 Criteria of designing ideal contrast agents 
In the design of ideal contrast agents, several factors must be considered. First, negligi-
ble or low toxicity is a prerequisite. The contrast agents should be thermodynamically and ki-
netically stable, with high binding affinity and metal selectivity to minimize the release of free 
Gd3+. A high metal selectivity for paramagnetic metal ions against physiological metal ions such 
as Zn2+ and Ca2+ is preferred [108-109]. Second, high relaxivity, especially for T1, is preferred in 
order to obtain better images with high contrast-to-noise ratio (CNR) and dose efficiency. Third, 
an ideal contrast agent should have proper vascular retention time allowing for imaging of tis-
sue enhancement, gauging tissue blood perfusion, and evaluating changes in capillary integrity. 
Different strategies are applied to overcome the drawback of small chelator based MRI contrast 
agents. For example, the non-covalent binding of small chelators to plasma proteins, such as 
albumin (MS-325), greatly increases the relaxivity and blood retention time. On the other hand, 
the applications of this class of contrast agents are limited to the cardiovascular system.  
Fourth, it should have proper excretion time from the body to allow imaging and reduced toxic-
ity. Molecules that are greater than 70 KDa do not readily pass through the glomeruli (a pore 
size 60-70 nm in diameter)[105]. For example, the blood retention time for MS-325 in rabbit is 
increased to over an hour[110]. The slow secretion and perfusion time for macromolecules 
such as nanoparticles may be a big concern. Finally, targeting specific molecular entities is 
greatly preferred since it will increase the specificity of MRI as a screening method for cancer 
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diagnosis with the advantage of nondestructive and spatial resolution. Molecular imaging using 
MRI contrast agents is also hampered by the low relaxivity, since in most cases these biomark-
ers have limited number in the disease area. To achieve molecular imaging, developing contrast 
agents with high dose efficacy, low toxicity, optimal pharmacokinetics, and the capability of 
targeting and permeabilty are required.  
 
1.8 Objectives of this study, and over view of the dissertation  
The Yang laboratory has first demonstrated MRI contrast agents (ProCA) with strong 
metal binding affinity, selectivity, and stability, developed by de novo design of Gd3+ binding 
site(s) into a stable host protein (Figure 1.12). The protein contrast agents exhibit ~20 fold im-
proved MRI relaxivity compared to that of Gd-DTPA at 1.5- 4.7 T field due to controlled correla-
tion time and exchangeable water numbers in the coordination shell [111]. Our study demon-
strated a novel strategy to significantly increase the relaxivity of contrast agents by protein de-
sign. 
There is an urgent need to develop non-invasive and accurate methods for diagnosis 
and to monitor biomarker levels/distribution and their changes upon treatment by targeted 
drugs in cancer patients. Based on the advantages of MRI of high resolution and deep tissue 
penetration and real time, we propose to further develop MRI contrast agents to extend its ca-
pability and application in both clinic and preclinical research.   
The goals of this research are to develop a novel class of protein-based MRI contrast 
agents (ProCAs) with improved relaxivity, targeting capability and reduced toxicity to enable 
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accurate monitoring of the expression level and distribution of the HER2/Neu and EGFR in dif-
ferent types of cancers, and to follow tumor response to treatment using targeted therapeutics. 
This dissertation aims to answer several important questions in order to apply this strat-
egy to develop MRI contrast agents for molecular imaging: 
Chapter 1 discusses the background and related knowledge of this dissertation. 
Chapter 2 describes all the methods and techniques have been used for this disserta-
tion. 
Chapter 3 discusses the design of HER2 targeting contrast agents. Methods for expres-
sion and purification of designed ProCAs with targeted capability have been optimized. Further 
modification of ProCAs to increase the solubility, serum stability and reduce the immunogene-
nicity will be achieved by PEGylation.  Dural modality of contrast agents for both MRI and NIR 
have been prepared and characterized.  Conformational and metal binding properties have 
been examined.   Furthermore, the relaxation properties have been measured. 
Chapter 4 is aimed to evaluate the targeting capability using several methods such as 
ELISA, western blotting and flowcytometry. The cell targeting capability has been evaluated us-
ing different cell lines with both NIR florescence and immunofluorescent staining. The adioac-
tive assay is also used to measure the retention of Gd3+ in cancer cells. In addition, EFGR tar-
geted contrast agents are also determined by the cell assays. 
Chapter 5 discusses the design of xenograft animal model with the injection of our de-
signed targeted MRI contrast agents. The optimized condition for imaging has been determined  
for both MRI and NIR of imaging HER2 under various time points. Further histology analysis for 
40 
primary organs shows biodistribution of HER2 and contrast agents. The advantages of ProCA1-
affi342 to antibodies are also determined by IHC. 
Chapter 6 shows quantitative analysis of the distribution and binding capability of Pro-
CA1-affi342 in cancer cells and animals. 
Chapter 7 is aimed to show development of another mouse model by implanting tumor 
cells in the mammary sites of mice as orthotopic tumor model, which can mimic the real tumor 
situation. ProCA1-affi342 and ProCA1-affi1907 will be applied to this tumor model to monitor 
the tumor progression and receptor distribution. 
Chapter 8 focuses on drug treatment study by using contrast agents to monitor the tu-
mor changes after treated with specific drugs. Initial results in cell treatments have been 
achieved by immunology techniques and MRI in cells. 
Chapter 9 summarizes other studies related to this dissertation by using designed con-
trast agents with multiple metal binding sites in developed xenograft models. 
Table 5 summarizes all the variants involved in this dissertation. 
The contents related with each variant have been listed in the Table 5: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
Table 5 Contents of all the variants 
Variants Description Related Chapters 
ProCA1-CD2 
Domain 1 of CD2 with a designed Gd3+ 
binding site 
1, 3 
ProCA1-affi4 
First generation of affibody ZHER2:4 against 
HER2 fused to the C-terminal of ProCA1-
CD2 
3, 4 
ProCA1-affi342 
Second generation of affibody ZHER2:342 
against HER2 fused to the C-terminal of 
ProCA1-CD2 
3-8 
ProCA1-affi1907 
Affibody ZEGFR:1907 against EGFR fused to 
the C-terminal of ProCA1-CD2 
8 
ProCA1-affi342m PEGylated ProCA1-affi342 3-8 
ProCA1-affi1907m PEGylated ProCA1-affi1907 8 
ProCA22-affi342m 
Second generation of affibody ZHER2:342 
against HER2 fused to the ProCA22 which 
has four metal binding sites 
9 
ProCA32-affi342m 
Second generation of affibody ZHER2:342 
against HER2 fused to the ProCA22 which 
has two metal binding sites 
9 
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Chapter 2. MATERIAL AND METHODS 
2.1 Molecular cloning of ProCA1-affibody to target HER2 and EGFR 
The affibody sequences ZHER2-2:4, ZHER2-342 and ZEGFR-1907 were cloned to the C-terminal of 
ProCA1-CD2 in the pGEX-2T plasmid. Their sequence alignments have been carried out by on-
line software Clustal W2 (Figure 1.9).  The affibody peptide consists of 58 amino acids and 13 
amino acids of them are involved in the targeting moieties, which are located in the helix 1 and 
2. The sequences have been divided into three fragments and inserted into the plasmid. The 
model structure of ProCA1-CD2 with Gd3+ binding site was been generated by SWISSMODEL 
[112-113]. The affibody structure was shown in Figure 1.9 [114]. The model structure of Pro-
CA1-affibody was generated by linking two parts of the structure files with GGSGG linker (Figure 
3.1). 
 
 
2.2 Plasmid construction and protein generation 
After the fusion of affibody into the ProCA-CD2 plasmid by PCR, the DNA products were 
prepared by Miniprep (Qiagen). All sequences were verified by automated sequencing on an 
ABI PRISM-377 DNA sequencer (Applied Biosystems) in the Advanced Biotechnology Core Facili-
ties of Georgia State University. Protein concentration is calculated using extinction coefficient 
of UV280 nm. 
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2.2.1 GST-fusion ProCA1-affibody and purification 
The designed ProCA1-affibody were expressed as GST-tag fusion proteins in Escherichia 
coli BL21(DE3) transformed with the plasmid constructs in LB medium with 100 mg/L of ampicil-
lin and were grown at 37 °C overnight. On the second day, 50-60 ml inoculating LB medium 
with the E coli Bl21 (DE3) is transfer to the big flask with 1L LB medium. 1ml amplicilin (1:1000) 
is added into the LB medium. The optical density (OD) of the cultured medium is measured at 
600nm. The big flask is shaking in37 ℃, 220rpm for cell growth. When the OD increases to 0.6-
0.8 (usually growth for 2 hours), the 1.5 mM IPTG is added into the LB medium, and the protein 
will be expressed. The cell pellets are collected when OD grows over 2.0 for further purifica-
tion. For low temperature expression, the temperature is changed to room temperature (25℃) 
after induction for 16~18 hours overnight. 
 
2.2.2 Sub-cloning of tagless ProCA1-affibody and purification 
The DNA sequence of ProCA1-affibody in PGEX-2T (Figure 2.1) vector was cleaved by 
BamH1 and EcoR1 restriction enzymes. The BamH1 site locates between GST tag and ProCA1-
affi, while EcoR1 site locates at the C-terminal of ProCA1-affibody. Then the DNA sequence of 
ProCA1-affibody was attached to the cleaved PET-20b vector (Figure 2.2). 
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Figure 2.1 DNA map of PGEX-2T vector 
 
Figure 2.2  DNA map of PET-20b vector 
 
45 
2.3 PEGylation of ProCA1-affibody 
Methyl-PEOn-NHS esters, the deviant of Polyethylene glycol (PEG) with different mole-
cular weights of 0.3, 0.6, 2.4, 5, 12 and 20 KDa were selected to modify the designed proteins. 
PEGylation was carried out in phosphate buffered saline buffer with a 1:5 ratio of protein and 
PEGs. Modified ProCA1-affibodies were further purified by FPLC and confirmed by the MALDI-
TOF mass spectrometric analysis. 
 
2.4 Conjugation of near infra red (NIR) dye to ProCA1-affibody 
A Cys amino acid has been cloned to the C-terminal of ProCA1-affibody by PCR. The 
Maleid group in the NIR dye can be linked to the –SH group specifically. The protein has been 
dissolved in degassed PBS (pH 7.0-7.5) by dialysis at a concentration around 1 mg/ml.  Tris-(2-
carboxethyl)phosphine (TCEP) was added to reduce the protein in N2 environment. Half an hour 
later, the NIR dye Cy5.5 in DMF solvent was added in to the reduced protein solution. The con-
jugation reaction was kept in N2 to keep reducing environment. The ratio of protein to Cy5.5 is 
around 5:1. Shake the mixture and keep the reaction for 2 hr. Then dialysis or cation exchange 
column will be used to separate the free dye. The absorbance at 650 nm (Cy5.5) and 280 (pro-
tein) will be measured to calculate the conjugation yield (Figure 3.16).  
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2.5 Determining the folding condition of ProCA1-affibody 
2.5.1 Mass spectrometry  
The MALDI mass spectrometry analysis was performed on an Applied Biosystems 4800 
plus MALDI TOF/TOF analyzer mass spectrometer (Framingham, MA). The data were acquired 
in a linear positive mode with sinapinic acid as matrix. The instrument was equipped with a Di-
ode-pumped Nd:YAG laser at 355-nm. The mass spectra were acquired as an average of 3 shots 
with a same laser intensity attenuator setting (4002 arbitrary unit) for all samples. Protein sam-
ples were prepared as a 200 μM solution in 10 mM Tris buffer (pH 7.4). Matrix was prepared as 
a 10 mg/mL solution of Sinapinic acid in a 1:1 acetonitrile: 0.1% TFA solution. A 10:1 ma-
trix:sample mixture was prepared, applied to the sample plate as 1 μL drops, and allowed to air 
dry. The molecular weight been measured indicates the conjugation of NIR dye to the ProCA1-
affibody proteins. The relative peak intensity ratio of the non-conjugated and conjugated Pro-
CA1-affibody was used for the estimation of the conjugation rate. This work was completed by 
Dr.Siming Wang and Yanyi Chen. 
 
2.5.2 Circular dichroism spectroscopy 
The CD spectra of samples were recorded in a Jasco-810 spectropolarimeter at 25 ºC. 
The far-UV CD spectrum of 20 μM ProCA1-affi342 were measured in a 1-mm pathlength cell in 
10 mM Tris-Cl (pH 7.4) and the near-UV CD spectrum of those protein studied with a concentra-
tion of 100 μM were collected in the same buffer. All spectra were obtained as the average of 
at least ten scans with a scan rate of 100 nm/min. The ellipticity was measured from 190 to 260 
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nm (far-UV) and 250 to 340 nm (near-UV) and then converted to mean residue molar ellipticity 
after subtracting the spectrum of buffer as the blank. 
 
2.5.3 Fluorescence spectroscopy 
Fluorescence emission spectra were recorded on a PTI fluorimeter at 25 ˚C using a 1-cm 
path length cell. Intrinsic tryptophan fluorescence emission spectra were recorded from 300 to 
400 nm with the excitation wavelength at 282 nm. The slit widths were set as 2 and 4 nm for 
excitation and emission, respectively. Tryptophan spectra from 300-400 nm of the different 
proteins studied were acquired at a concentration of 2 µM in 10 mM Tris-Cl (pH 7.4). 
 
2.5.4 Nuclear Magnetic Resonance (NMR) spectroscopy 
NMR spectra were collected on a 600 MHz NMR spectrometer. 1-D 1H-NMR at 25 °C was 
measured to determine the folding of ProCA1-affibody and the conjugation with NIR dye. This 
part of work was done by Dr. Hing Wong. 
 
2.6 Relaxivity measurements and metal binding affinity of ProCA1-affibody 
Relaxation times, T1 and T2, were determined on the 1.41T Minispec Relaxometer 
(mq60 NMR Analyzer, Bruker) at 37 °C. The ProCA1-affi and ProCA1-affi-m (modified by PEG) 
were diluted with 10 mM Tris buffer, pH7.0. Proteins prepared with a series of concentrations: 
40-120 µM, were applied for the relaxation time measurement. The relaxivities, r1 and r2, were 
obtained by fitting the relaxation times as a function of the Gd3+ concentrations. The Gd3+ -
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binding affinities with ProCA1-affi and ProCA1-affi-m were investigated by the competitive as-
say with the dye Fluo5N (a metal ion indicator, Invitrogen Molecular Probes). The fluorescence 
spectra were collected on a fluorescence spectrophotometer (Photon TechnologyInternational, 
Inc.) with a 10 mm path length quartz cell at room temperature [111]. 
 
2.7 Cell culture and mammalian expression 
SKOV-3 cells were cultured in 5% CO2 at 37˚C in 75 cm
2 flasks in McCoy-5A medium con-
taining 10% fetal bovine serum (FBS) with 100 μg/ml Penicillin-Streptomycin. The other mam-
malian cancer cell lines are cultured in the same condition with different medium The AU565 
cells were cultured in 1640 medium. The MDA-MB-231 cells were cultured in DMEM medium 
with low glucose. The EMT-6 cells were cultured in waymouth medium. All the cells were thaw 
at 37 ˚C and transferred into a 25T flask with 8 ml medium. After growing to a confluence over 
90%, the cells will be suspended by 2% Trypsin and washed with HBSS buffer by centrifuging. 
Finally the cells are passaged into several 50T or bigger flasks. The cells were frozen in commer-
cial frozen medium containing 2% EDTA and 10% DMSO. Normally, about  106 cells will be fro-
zen in 1 ml frozen medium. 
For the mammalian expression, the LEC1 HER2 pSGHV0 cell line with stable transfection 
of HER2-ECD DNA was obtained from Dr. Leahy’s group in Johns Hopkins University. The cells 
were thawed rapidly at 37 ˚C. Spin the cells for 5 minutes at 1000rpm and aspirate freezing me-
dia.  The cells were re-suspend in 1 ml  Alpha MEM, 5%Dialized FBS, 100nM Methotrexate, 0.5 
mg/ml geneticin.  The cells were then transferred to 4 ml of the same in a T25 flask, 5%CO2, 37 
degrees.  Once expanded to have enough cells to seed a roller bottle (3-5 confluent T150's 
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would do it), they are switched to DMEM / F12, 5%FBS, 100nM MTX.  Weekly monitoring of ex-
pression medium by ELISA was done to ensure expression has not lost.  The DMEM / F12 is 
HEPES buffered since our roller apparatus is without CO2.  Once the single roller bottle is con-
fluent, we use that to split into 1L flasks.  After 3 days in 5% serum to insure attachment, serum 
is reduced to 1% for collection of media and further purification.  The 1L flasks are generally fed 
50 ml /flask, twice a week.   
 
2.8 Cancer cell targeting 
2.8.1 Enzyme linked immunosorbent assay (ELISA) 
The cell lysate was made for the coating of ELISA. Take one flask of cancer cells and sus-
pend with 2% Trypsin. Wash the cells for three times and count 1×108 of cells into a centrifuge 
tube. The 1 ml RAPI buffer and 0.1% protease inhibitor cocktail was added into the cell pellets. 
The cells were suspended and keep in 4 ˚C for 1 hr shaking. Centrifuge the cells and get the su-
pernatant as cell lysate. AU565 and EMT-6 cells lysate with various dilutions was coated in a 96-
well plate (BD bioscience) at 37 °C degree overnight. On the second day, the medium was 
changed. Different amounts of ProCA1-affi342 and ProCA1-affi342m were incubated with cells 
for 1 hr in room temperature. The plate was washed and the CD2 antibody was used as a pri-
mary antibody to detect the binding proteins in the cells. HRP conjugated goat anti-mouse IgG 
conjugated was used as the secondary antibody. Substrate (OPD,o-phenylenediamine dihydro- 
chloride) was added into each well. After incubation, the absorbance was measured at 492nm 
using a Victor V 1420 multiple counter from PerkinElmer. 
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In the sandwich ELISA, the CD2 monoclonal antibody was coated on 96-well microplate 
at a concentration of 100ng/well with carbonate/bicarbonate buffer (pH 7.4) and incubated at 
4°C overnight. The second day, coating buffer was removed and the plate was washed with Tris 
buffer saline (TBS) three times. The remaining protein-binding sites in the coated wells was sa-
turated by adding 200 μl blocking buffer (5% nonfat dry milk/TBS, per well). The plate was cov-
ered and incubated for 2 hours at room temperature. Diluted proteins or tissue extracts from 
mice experiment were added to each well and incubated at 37°C for 2 hours. Each cell treat-
ment was done in triplicate. TBS was used to wash each well three times after incubation. Di-
luted polyclonal CD2 antibody was added to each well and incubated at room temperature for 2 
hours. The plate was washed with TBS four times. HRP conjugated secondary antibody was 
added to the 96-well plate in blocking buffer and incubated at room temperature for 2 hours. 
After incubation, the plate was washed four times with TBS. The substrate of HRP was prepared 
for detection of protein signals. OPD (ophenylenediamine dihydrochloride) was used as the 
substrate. After incubation, the absorbance was measured at 492nm using a Victor V 1420 mul-
tiple counter from PerkinElmer. 
 
2.8.2 Western blotting 
The AU565, originally from human breast cancer, has an expression level of HER2 at 
about 106 per cell. The EMT6 is a HER2 negative cell line from mouse breast cancer. The Pro-
CA1-affi342 and ProCA1-affi342m were incubated with the two kinds of cells at 4 and 37 °C, re-
spectively, for 1 hr. Then the cells were washed 3 times, 5 min each with Tris buffer. After this, 
the cells in T25 were lysate with 200 µL RAPI buffer for 3 hr in 4 ˚C. Then the cell lysate was cen-
51 
trifuged and the supernatant was collected for western blotting. The primary antibody was 
generated on rabbit by using ProCA1-CD2-m as antigen. The secondary antibody was AP conju-
gated (Invitrogen). The ProCA1-affi342 or ProCA1-affi342m retained in the cancer cells will be 
detected by antibody and the signal will be shown on the developed film. 
 
2.8.3 Radio-active assay on cancer cells 
Cancer cells AU565 and EMT-6 were collected into 1.7 ml tubes by trypsin and centrifug-
ing.  After careful washing 3 times with HBSS buffer, the cells were incubated with radioactive 
reagent 153Gd-ProCA1-affi342 and 153Gd-ProCA1-affi342m. 153GdCl3 (Novagen) was also used as 
negative control. The incubation time is 1 hr by shaking. Then the cells were spin down by keep-
ing both the pellets and supernatant. Wash the cells with HBSS buffer for 5 times, the washing 
buffer was also collected. Finally, all the samples including cell pellets and washing buffer were 
measured by γ-counter. The amount of 153Gd retained in the cancer cells was calculated based 
on the standard curve (Figure 2.3). 
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Figure 2.3 Standard curve of radioactive GdCl3 
 
2.8.4 Immunofluorescent staining in cancer cells 
Three cell lines (AU565, SKOV-3 and MDA-MB-231) were seeded in different chambered 
microslides (BD Biosciences) and treated with ProCA1-CD2, ProCA1-affibody, and ProCA1-
affibody-m at 37°C for one hour. The second day, cells were washed and fixed with 4% para-
formadehye for 15 minutes at room temperature. Then cells were permeabilized with 0.1% Tri-
ton X-100 in 10 mM HEPES pH7.0. ImageiTTMFX signal enhancer (Molecular Probes) and subse-
quently incubated with the respective antibodies for 1 hour. After extensive wash, cells were 
incubated with Alexa Fluor 488nm goat anti-mouse IgG (Molecular Probes) at a 1:1000 ratio. 
Cells were washed three times for 5 minutes with TBST. Finally, microslides were mounted in 
ProLong Gold antifade reagent with DAPI (Molecular Probes). Slides were scanned in a confocal 
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microscopy lab with the Confocal Microscope (Zeiss. LSM510) using 40x or 63x objectives. Two 
lasers were used here, 488nm for FITC and blue for UV. The final images were acquired by ad-
justing detector gain and amplifier offset to get the best images. 
 
2.8.5 Flow cytometer assay (FACS) 
The cancer cells SKOV-3 and MDA-MB-231 were cultured for the flow cytometer study. 
The cells were lysated and suspended to transfer into a 5 ml FACS tube. The cells were washed 
for 5 times by HBSS buffer. Then the PAb-ProCA1-CD2 (Appendix I) was added into the cells 
with 1:500 dilutions. After 1 hr incubation in room temperature, the cells were washed with 
HBSS buffer for 3 times. Secondary antibody goat anti rabbit with FITC conjugation was added 
and incubate for 40 min. After extensive washing, the cells were counted by the FACS machine 
with the number of 2,000. The accumulated fluorescent intensity was measured. 
 
2.8.6 Magnetic Resonance Imaging (MRI) in cancer cells 
SKOV-3 and MDA-MB-231 cells were collected and washed with 10 mM HEPES buffer 
(pH7.0) three times. Up to 107 cells were incubated with Gd-ProCA1, Gd-ProCA1-affibody and 
Gd-ProCA1-affibody-m at 37°C for 1 hour. After incubation, cells were washed with TBS three 
times, 5 minutes each time. Cell pellets were collected in eppendorff tubes and measured by 
MR imaging. T1 weighted MR images were acquired using an inversion recovery sequence (TR = 
4000ms, TE = 12ms, IR=500ms) on a 7T MRI scanner. After cell MR imaging, cells were washed 
twice with ice-cold PBS. PBS was removed and cell pellets were lysed with 1×RIPA lysis buffer 
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supplemented with 1mM NaF, 1mM PMSF and 1:1000 dilution of protease inhibitor cocktail. 
Whole cell lysates were rotated at 4°C for 60 minutes. To remove cell debris, cell lysates were 
centrifuged (15,000×g, 10min at 4°C). Cell lysate supernatant was collected and stored at -80°C 
until use. 2× loading dye was added to the supernatant and boiled at 100°C for 5 minutes. 
Western blotting was applied to check the contrast agent in cells by using the CD2 antibody 
against the contrast agents. 
 
2.9 Animal experiments 
2.9.1 Nude mouse xenograft model 
The nude mice are two weeks old. In 3-5 days after purchase, the mice are ready for 
use. The tumor cells are scratched from flask and washed with HBSS buffer for three times. The 
cells are counted and then suspended with saline to get a suspension of 5×106 cells per 100 µl 
saline. The suspension is mixed with gel matrix in same volume. This procedure is completed on 
ice. Every mouse is subcutaneous injected with 100 µl mixture on each spot. Every mouse has 
two or three spots on its back. After two to three weeks, the mice will generate tumor of 0.5-1 
cm.  
 
2.9.2 Nude mouse othotopic model 
The human breast cancer cell line MCF-10DCIS was used to generate the othotopic 
model in nude mice. The tumor cells are scratched from flask and washed with HBSS buffer for 
three times. The cells are counted and then suspended with saline to get a suspension of 5×104 
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cells per 50 µl saline. Inject the cells into the mammary spot of the mouse. After about one 
week, the tumor between 0.5 to 1 cm will be generated. 
 
2.9.3 Magnetic Resonance Imaging (MRI) of tumor mouse 
The tumor mouse will be anesthetized with constant isoflurane and located in the MRI 
machine for a pre-injection scanning. The tumor mouse will be injected by tail vein injection 
with our contrast agents in 10 mM HEPES buffer, pH7.0. The concentrations of our contrast 
agents are between 3 to 5 mM. About 100 µL of the contrast agents will be injected into each 
mouse. The mouse will be scanned on a 4.7 MRI scanner at various time points after injection: 
10 min, 30 min, 2 hr, 24 hr, 48 hr and 72 hr. For every time point, three pulse sequences are 
used: Fast spin echo (TR=2 s, TE=0.022 s or 0.066 s) Gradient echo (TR=0.116 s, TE=2.9 s ) Gra-
dient echo DCE (TR=0.050 s, TE=2.9 s ) 3D image of Gradient echo was also scanned. 
 
2.9.4 Near infra-red (NIR) imaging of tumor mouse 
Engineered protein contrast agents were PEGylated and labeled with Cy5.5 (ProCA1-
affibody-Cy5.5). The protein was stored in 10mM HEPES buffer at concentration of roughly 
5mM. 100 µL of Cy5.5 PEGylated protein was injected into the mouse tail vein. Fluorescence 
imaging was taken at different time points using an IVIS imaging system (Xenogen Corporation). 
The mouse was maintained under isoflorane anesthesia during imaging. Images were processed 
using the living imaging 3.1 from Xenogen Corporation. The excitation filter wavelength of 650 
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nm was used to scan the mouse NIR imaging. Another excitation wavelength of 604 nm was al-
so used to scan the background. The emission wavelength is 740 nm. 
 
2.9.5 Biodistribution and blood circulation measurements 
The biodistribution of ProCA1-affi342m has been measured in the regular CD1 mouse 
and nude mouse with tumors. The mice will be kept in the metabolism cages for 2 days before 
experiments. Then mice were injected with 100 µM 153Gd-ProCA1-affi342m in 10 mM HEPES 
buffer (pH7.0) of 100 µL by tail vein injection. The mice are all kept in the metabolism cages in-
dividually under monitoring. The total monitoring time is 8 hours. All the urea and feces will be 
collected. The blood will also be collected from thigh vein every 1 hr. At the end of 8th hour, all 
the mice will be sacrificed and dissected. All the primary organs, like liver, kidneys, lung, heart, 
spleen, tumor and muscle were collected for measurements, as well as the carcass. The ra-
dioactivity of all the collected organs and blood samples will be measured by γ-counter. From 
the standard curve of Figure 2.3, the amounts of 153Gd in each organ or blood were calculated. 
Then the amount of 153Gd will be divided by the total injection amount and bodyweight to get a 
normalized percentage of each sample in each organ per kg of body weight. 
 
2.9.6 Biodistribution measurements by ICP-OES 
Besides using radioactive assay for the biodistribution study, we also used ICP-OES to 
measure the retention of Gd inside the mouse body. After MRI experiments, we collected all 
the primary organs, like liver, kidneys, lung, spleen, heart, tumor and muscle. All the organs 
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were dissolved in 30% optimal nitric acid in the containers. The containers were heated at 80-
100 ˚C overnight until all the organs were dissolved. Based on the previous radioactive distribu-
tion results, the dissolved organ solution will be diluted by 2% optimal nitric acid to the mea-
surement range of ICP-OES (50-5000 nM). By measuring the intensity of two excitation wave-
lengths at 368.4 nm and 342.2 nm [115], the concentration will be obtained based on the 
commercial GdCl3 samples.  The original Gd
3+ concentration in all the samples was calculated by 
multiplying the measured concentration with dilution times. 
 
2.10 Histology analysis 
2.10.1 Preparation of tissue slices 
After MRI experiments, all the organs will be frozen in liquid Nitrogen with OCT embed-
ded. Then the frozen tissue will be kept in -80 ˚C. Before section the tissues, the frozen samples 
have to be removed from freezer and equilibrate at -20°C for approximately 15 minutes. This 
may prevent cracking of the block when sectioning. Section tissue at a range of 6-8 µm and 
place on positively charged slides. Allow sections to air dry on bench for a few minutes before 
fixing (this helps sections adhere to slides). 
After sections have dried on the slide, they will be fixed in optimal fixative (10% Neutral 
buffered formalin) for 10 minutes at room temperature. The staining procedure will be pro-
ceeding immediately.  
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2.10.2 Immunohistology chemistry (IHC) on paraffin embedded slices 
The paraffin on the section needs to be removed before staining by Xylen and the stain-
ing procedure will be proceeding immediately. First, wash sections in water three times for 5 
minutes each. Incubate sections in 3% hydrogen peroxide for 10 minutes. Wash sections in wa-
ter twice for 5 minutes each. Wash section in HEPES buffer for 5 minutes. Block each section 
with 100-400 μl blocking solution for 1 hour at room temperature. Remove blocking solution 
and add 100-400 μl primary antibody diluted in recommended antibody diluent to each section. 
Incubate overnight at 4°C. Remove antibody solution and wash sections in wash buffer three 
times for 5 minutes each. Add 100-400 μl HRP conjugated secondary antibodies, diluted in 
HEPES buffer with 1% Triton, to each section. Incubate 30 minutes at room temperature. If us-
ing ABC avidin/biotin method, prepare ABC reagent according to the manufacturer’s instruc-
tions and incubate solution for 30 minutes at room temperature.  
Remove secondary antibody solution and wash sections three times with wash buffer 
for 5 minutes each. Add 100-400 μl DAB or suitable substrate to each section and monitor stain-
ing closely. As soon as the sections develop, immerse slides in water. If desired, counterstain 
sections in hematoxylin. Wash sections in dH2O two times for 5 minutes each.  
 
2.10.3 Immunofluorescent staining on frozen slices 
Wash sections in wash buffer twice for 5 minutes. Incubate for 10 minutes at room 
temperature in 3% H202 diluted in methanol. Wash sections in wash buffer twice for 5 minutes. 
Block each section with blocking solution for one hour at room temperature. Remove blocking 
solution and add 100-400 µL diluted primary antibody to each section. (Dilute antibody in 
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blocking solution). Incubate overnight at 4°C. Refer to product datasheet to determine the rec-
ommended dilution. Remove antibody solution and wash sections three times with wash buffer 
for 5 minutes each. Add 100-400 µL secondary antibody with fluorescent dyes labeled, diluted 
in blocking solution to each section. Incubate 30 minutes at room temperature. Remove sec-
ondary antibody solution and wash sections three times in wash buffer for 5 minutes each. Add 
anti-fade reagents with DAPI dye on the section and seal the tissue section with nail polish.  
 
2.11 Measure immunogenecity of ProCA1-affi 
PEGylated contrast agents (P40-ProCA1-affi) and non PEGylated ProCA1-affi with or 
without adjuvant were injected into rabbits for antibody generation. The first injection was 
mixed with Complete Freund’s Adjuvant  and the subsequent boosts (every 2 to 3 weeks) were 
mixed with Incomplete Freund’s Adjuvant. Rabbit blood was collected at different time points 
(every two to three weeks). Each time, 10ml blood was collected and centrifuged. The serum 
was collected in clean tubes and stored in -80°C. The immunogenicity of P40-ProCA1 was ana-
lyzed by western blotting and ELISA. 
 
2.12 Measurement of Acute toxicity 
The 2 mM of ProCA1-affi-m in 100 µL saline was injected into the two regular CD1 mice 
in each group for toxicity analysis. The control group was injected with 100 µL saline only. After 
2 days, the mice were sacrificed and blood was collected to get the blood serum. The enzymes 
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of creatinine and ALT, ALP in the blood serum were measured to analyze the toxicity in kidneys 
and liver (Research Animal Diagnostic Laboratory, University of Missouri). 
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Chapter 3. DESIGN, PREPARATION AND IN VITRO CHARACTERIZATION OF HER2 TARGETD 
PROCA1 USING AFFIBODY  
3.1 Introduction 
As one of the most advanced imaging techniques, MRI plays an important role in clinical 
diagnosis and treatment [116]. Therefore, in recent decades, the development of MRI contrast 
agents has been the hottest topic in radiology because of the unique characteristics of MR im-
ages [117-118]. However, there are limitations for MRI application in the clinic due to its low 
sensitivity and specificity. As discussed in Chapter 1.6, molecular imaging of MRI requires con-
trast agents for significantly improved relaxivity since relaxivity determines the sensitivity of the 
MRI contrast agents [119].   The relaxivity of about 5mM-1s-1 of current approved MRI contrast 
agents such as DTPA could not detect biomarkers with  expressed numbers of up to 106 on the 
cell surface (Figure 1.7) [18]. Therefore, there is a strong need to develop MRI contrast agents 
with a high relaxivity and targeting capability for molecular imaging of disease biomarkers 
[120].  
Previously developed protein-based MRI contrast agent (ProCA1-CD2) in the Yang labo-
ratoryshowed high relaxivity with 10-20 folds increased compared with DTPA (Figure 
3.11)[111].The designed contrast agents were created by designing a metal binding site in do-
main1 of CD2. By developing protein based MRI contrast agents, there are several advantages: 
first, larger water number enables higher relaxivity than small chelators; second, protein is con-
venient to covalently link with other ligands for targeting to biomarkers; third, humane proteins 
can eliminate side effects. 
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In order to produce MRI contrast agents with high relaxivity for clinical application, 
there are several challenges. First, we need develop a method to express and purify proteins 
with high yield and low cost. Current injection dose for mice for DTPA is 50 mmol/kg [121]. 
Second, we need increase solubility of the protein MRI contrast agent. If our contrast agent has 
a 10 fold increase in relaxivity, protein concentration of 1 mM is required. However, the solubil-
ity of ProCA1 is less than 0.7 mM. Although conjugated small chelator molecule such as DTPA to 
soluble macro molecules may produce large surface exposure to water and some increase the 
relaxibity [107, 122], large molecules always have the problem in solubility and tissue penetra-
tion.  Third, Gd3+ is the most common used metal for MRI contrast agents since this molecule 
has seven free electrons [123]. In order to prevent the competitive binding of physiological 
metals such as Ca2+, Mg2+ and Cu2+ binding to the contrast agent cheletors, strong metal selec-
tivity should be achieved in designing the MRI contrast agents. In addition, stability of protein-
Gd complex is important to prevent the release of free Gd3+ that is linked to NSF (nephrogenic 
systemic fibrosis). It is important to maintain relaxivity and serum stability under different con-
ditions.  Finally, the targeted protein contrast agent against biomarker will provide us with mo-
lecular specificity to against the tumor and further reduce the adverse effect.   
In this chapter, we will first discuss our rationale in designing a new protein-based MRI 
contrast agent called ProCA1-affi342 with the addition of an affibody, which is capable of pro-
ducing a molecular image of breast cancer by targeting to biomarker HER2. We have developed 
a novel multimodal molecular imaging probe to target cancer marker HER2/neu using magnetic 
resonance and near infrared imaging (NIR) (Figure 3.3). We employed a protein-based MRI con-
trast moiety (ProCA1) that was developed by de novo designing the Gd3+ binding site(s) into a 
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stable host protein, the domain 1 of rat CD2 (10 KDa). Due to the unique features of the de-
signed metal binding properties, the protein contrast agent exhibited a significant improved T1 
relaxivity for MRI contrast enhancement compared to that of commonly used Gd-DTPA (Diethy-
lenetriamine Pentaacetic Acid) at 1.4- 4.7T field strength [111]. A high affinity HER2 affibody 
[37, 72] was engineered into the C terminal of the designed Gd3+-binding protein by a flexible 
linker.  The small molecular size (16 KDa) provides good tissue penetration. We also introduced 
an optical imaging capability by conjugating a near-IR dye Cy5.5 to a Cys residue at C-terminal 
of the protein to facilitate imaging analyses (Figure 3.3). To increase protein solubility, blood 
circulation time, and reduction of immunogenicity, the designed HER2 targeting protein con-
trast agent was PEGylated using PEG-40, a molecule with tri-branches of 12 units PEG (denoted 
as ProCA1-affi343-m) (Figure 3.1)  The protein generation method was optimized to obtain a 
high production yield. The biophysical characterization of conformational properties, the metal 
binding affinity and selectivity, and relaxivity were performed using various spectroscopic me-
thods. 
 
3.2 Results and Discussion 
3.2.1 Designed HER2 targeted protein based contrast agent with one Gd3+ binding site 
Figure 3.1a [111] shows the model structure of the designed protein-based MRI contrast 
agent (ProCA1-CD2). It was designed with following considerations: First, ProCA1 a designing a 
metal binding site in domain1 of CD2 was used. Second, a targeting peptide called affibody 
ZHER2:342 was cloned to the C terminal of ProCA1-CD2 (Figure 3.2). As discussed in Chapter 1 
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(1.4), affibody ZHER2:342 with 58 amino acid has a strong binding affinity to HER2 that is compari-
ble to antibody of 22 pM. The small size of affibody will provide a better tissue and tumor pene-
tration. Third, a flexible five residues GGSGG linker is added between affibody and ProCA1 to 
avoid the interference between them. Thus the contrast capability of ProCA1-CD2 and Target-
ing capability of affibody to the biomarkers, like HER2 and EGFR are expected to be not altered 
much. 
 
Figure 3.1 Model Structure of ProCA1-CD2 and PEGylated ProCA1-CD2 
(A) The model structure indicates the metal binding pocket with four Aspartates (D) and 
one Glutamate (E). The PEG chain can be conjugated to the Lysine (K) to produce hydrophilic 
surface and increase the exchangeable water number. (B) The PEGylation sites locate in the ly-
sine which has free amine residue. 
 
In order to make the ProCA1-affi342 suitable for in vivo imaging with high solubility, low 
immunogenicity and proper blood retention time, we further improved the protein based con-
trast agents ProCA1-affi342 for in vivo imaging by protein modification with various sizes of po-
lyethylene glycol (PEG) chain (‘PEGylation’). Figure 3.1 shows the modeled structure of the de-
signed contrast agent ProCA1-CD2 with Gd3+ binding site and the cartoon structure of the sec-
ondary and outer sphere water molecules associated with PEG chain.   
ABA
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Figure 3.2 Model Structure of ProCA1-affibody.  
 
The affibody was linked to ProCA1-CD2 by a flexible linker. Both ProCA1-CD2 and affibo-
dy keep their original folded structure. The ProCA1-CD2 functions as contrast agent domain, 
which will have MRI signal in magnetic field. The affibody provides the targeting domain to bind 
the disease biomarkers. 
 
 
Since MRI technique has relatively low sensitivity, we also created a duel modality for 
the ProCA1-affi342 (Figure 3.3) by addition of fluorescence probe with high sensitivity.  A Cyste-
ine was added by gene cloning to the C-terminal of ProCA1-affi342. The NIR (Near infra-red) dye 
Cy5.5 with maleimide group was conjugated to the Cysteine residue. The NIR image with high 
sensitivity can help to probe our MRI contrast agents in achieving molecular imaging. 
 
Affibody
ProCA1
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Figure 3.3 Construction of ProCA1-affi342. 
The model structure of multimodal HER2 targeted MR imaging probe created by con-
necting a high affinity HER2 affibody ZHER2-342  at the C-terminal of a de novo designed protein 
contrast agent ProCA1.CD2 with a designed Gd3+ binding site.  A near IR fluorescence dye Cy5.5 
was then conjugated to the added Cys at the C-terminal of the fusion protein.  The designed 
probe was further modified by a tri-branched polyethylene glycol (PEG) with 40 PEG subunits 
(ProCA1-affi342-m). 
 
 
To compare the specificity of targeting, we have also created a series of ProCA1-
affibodies, such as ProCA1-affi-WT, ProCA1-affi2-4 and ProCA1-affi342 (Figure 1.9). It is re-
ported that affibody342 has highest binding affinity (Kd=22 pM) with HER2-ECD [72]. Our cell 
binding data also indicates that ProCA1-affi342 has strongest binding with HER2 overexpressed 
cells. Therefore, affibody342 was selected as our targeting sequence. 
 
3.2.2 Generation of targeted ProCA1-affi342 
In order to get high yield of ProCA1-affi342, two methods for expression and purification 
such as GST-fusion and Tagless methods have been studied.  
ProCA1 AffibodyGd3+
HER2 
GGSGG 
 linker 
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Figure 3.5 shows the expression of GST fusion of ProCA1-affi342 using PGEX-2T vector 
with ampicillin antibiotic property. The protein was expressed in LB medium at 37 ˚C for 6 
hours. Then the ProCA1-affi342 was purified by GS-4B column with GST fusion at the N-
terminal. After the purified protein (Figure 3.4) was eluted by PBS (Phosphate buffer saline), the 
protein was PEGylated with PEG-40 directly in PBS, pH 7.4. The reaction needs 1-2 hr in room 
temperature, and then the PEGylation was stopped by free amino acids like glycine. The protein 
was further purified by cation exchange SP column (Figure 3.6). SDS-gel had been stained by 
coomassie blue for protein and Iodine for PEG (Figure 3.7). From the first step, 40-80 mg/L of LB 
medium proteins can be obtained. The yield of further purification is 80-90%. 
 
Figure 3.4 Purification Scheme 
The procedure of GST scheme (black line) needs three days of the whole procedure, 
while refolding assay takes one week to get a purified protein. 
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Figure 3.5 SDS gel of expression and initial purification by GS-4B column 
The highest expression level of ProCA1-affi342 reached 3 hours after induction with 
IPTG. After cleaved from GST tag by Thrombin, the pure protein was eluted from the GS-4B col-
umn.  
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Figure 3.6 Purification of PEGylated ProCA1-affi342 with cation exchange column 
The ProCA1-affi342m was purified by pH gradient. The protein was eluted out between 
pH7.2-7.4. The elution peak is not asymmetry because the PEGylated ProCA1-affi342 is a mix-
ture with different PEGylation number. 
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Figure 3.7 SDS gel of purified ProCA1-affi342m from SP column 
After purification, the free PEG reagent has been removed. The SDS-PAGE gel has been 
stained with Iodine and coomassie blue in consequence. The coomassie blue stains for proteins 
and the Iodine stains for PEG residues. 
 
 
For the tagless method, the DNA of ProCA1-affi342 was sub-cloned to PET20b vector. 
The protein expressed was tagless and insoluble in the inclusion body (Figure 3.8). After refold-
ing with Urea, the protein was purified by cation exchange SP column to obtain a pure protein  
The refolded protein obtained from inclusion body cause lower stability and the refold-
ing procedure is time consuming (Figure 3.4). Since the purified protein from GST fusion me-
thods are more soluble and folded, we decide to use GST fusion method to purify targeted pro-
tein contrast agent. 
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Figure 3.8 Expression of ProCA1-affi342 in PET20b vector 
The expression of ProCA1-affi342 in different E. coli shows that the expression level in 
tuner strain is much high than that in BL21(DE3). 
 
 
 
3.2.3 Conformational analysis of ProCA1-affibody  
The tryptophan fluorescent spectrum (Figure 3.8) and far UV CD (Figure 3.9) were used 
to exam the secondary structure of ProCA1-affi342. The excitation wavelength for the fluores-
cent scan is 280 nm; the emission range is 260-420 nm. The far UV CD spectrum at the range of 
190-260 nm was scanned to compare the secondary structure of ProCA1-affi with its original 
protein ProCA1-CD2. 
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Figure 3.9 Tryptophan Fluorescence measurement.  
The ProCA1-CD2 or ProCA1-affi342 of 5 µM concentration in HEPES buffer (10 mM, 
pH7.2) was measured in 10 mm cuvette. The excitation wavelength for the fluorescent scan is 
280 nm; the emission range is 260-420 nm. Compare with the host protein ProCA1-CD2, the 
emission peak of ProCA1-affi342 is red shifted due to the fusion with affibody. 
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Figure 3.10 The secondary structure measured by CD. 
 The ProCA1-CD2 or ProCA1-affi342 of 20 µM concentration in HEPES buffer (10 mM, 
pH7.2) was measured in 1 mm cuvette. The far UV CD spectrum at the range of 190-260 nm 
was scanned to compare the secondary structure of ProCA1-affi with its original protein Pro-
CA1-CD2. 
 
 
 
 
 
3.2.4 Modified ProCA1-affibody has been increased both in metal binding affinity and relax-
ivity 
The designed MRI contrast agent was expressed in E. coli and subsequently purified 
(Figure 4.2). The binding affinity was measured by competitive assay using dye Fluo5N. The eq-
-CD2
342
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uation 1 was used to calculated the Kd. Similar to the parental protein ProCA1-CD2, the de-
signed protein (ProCA1-affi) had a strong metal binding affinity with Kd for Gd
3+ at 1.86 x 10-12 
M [111] (Figure 3.10). ProCA1-affi also exhibited R1 and R2 relaxivities of 21 and 30 mM-1s-1 at 
1.41 T, respectively (Figure 3.11). PEGylaton resulted in about 15% increases in the relaxivity for 
both R1 and R2 [124]. The developed protein with conjugated NIR dye exhibited fluorescence 
excitation and emission maxima at 640 and 695 nm, respectively, and excitation coefficient 
constant of 0.21 µM-1cm-1 (Figure 4-3).   
𝑓 = ([𝑃]𝑇+[𝑀]𝑇+𝐾𝑑)−�([𝑃]𝑇+[𝑀]𝑇+𝐾𝑑)2−4[𝑃]𝑇[𝑀]𝑇
2[𝑃]𝑇                 (Equation 1) 
 
 
Figure 3.11 Metal binding affinity measurement.  
The metal binding of ProCA1-affi342m with Gd3+ was measured by competitive method 
using Fluo5N [111]. The binding affinity of Kd is 1.86 x 10
-12 M. 
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Figure 3.12 Relaxivity of ProCA1-affibody.  
The relaxivity of ProCA1-affi342 with (gray) and without PEGylation (ProCA1-affi342m, 
black) and clinically used Gd-DTPA (white) were measured under the magnetic field of 1.41 T at 
37 °C. The developed contrast agent exhibited 5-6 fold greater relaxivity in both r1 and r2. 
 
3.2.5 Other improved properties for modified contrast agents 
Modifying the proteins with PEG may have advantages in increasing solubility, which 
enables the ProCA1-affi342 to be concentrated to 5 mM for animal experiments. The stability of 
ProCA1-affi342 and ProCA1-affi342m was compared by keeping the protein in 37 ˚C overnight. 
Figure 3.12 shows that the PEGylated ProCA1-affi342m is much more stable than the original 
ProCA1-affi342. PEGylation well protects the protein from degradation and cleaving by pro-
tease. The immunogenicity was further studied by western blotting. Antibody generativity 
against the protein contrast agent (both PEGylated and native protein) in the rabbits was ex-
amined by western blotting. The experiments were carried out by SDS-PAGE of ProCA1-
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PEG2.4k, ProCA1-PEG0.6k and ProCA1 and detected by anti-serum collected from immuno-
inoculated rabbits. The results showed that addition of adjuvant induced stronger immune res-
ponses. PEGylation modifications of the protein dramatically reduced immune responses in the 
rabbits. Figure 3.13 suggests that the immunogenecity of the protein contrast agent may not be 
very strong, especially without addition of adjuvant. 
 
Figure 3.13 SDS gel to measure the stability of modified contrast agent 
The Gel shows that after staying in 37 ˚C for overnight, the original protein without PE-
Gylation had some degradation, however, the PEGylated protein did not have much change. 
 
Protein in 4˚C Protein in 37˚C 
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Figure 3.14 PEGylation substantially reduced the immune responses monitored by poly-
antibodies. 
The commercial CD2 polyclonal antibody PAb-ProCA1 was used as positive control (D). 
The other antiserum was prepared from the blood collected after two times of injection of na-
tive protein ProCA1 mixed with adjuvant (A). ProCA1  in the absence of adjuvant (B). ProCA1 -
PEG2.4k mixed in absence of adjuvant (C).  
 
 
3.2.6 Dual label ProCA1-affibody with NIR dye 
In order to create a dual moiety for contrast agent for both MRI and optical imaging, a 
NIR dye Cy5.5 (Figure 3.15) was conjugated to the ProCA1-affibody. Before conjugation, extinc-
tion coefficient of the dye in PBS buffer was measured (Figure 3.15). The conjugation efficiency 
can be calculated from the UV-VIS absorbance (Figure 3.16) and extinction coefficient of pro-
tein (Obtained from Protein Calculator) and dye.  
 
Figure 3.15 Chemical structure of Cy5.5 dye (GE Health care) 
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Figure 3.16 Extinction Coefficient of Cy 5.5 was measured 
The dye Cy5.5 was dissolved in HEPES buffer at four different concentrations: 10 µM, 25 
µM, 45 µM and 90 µM. The absorbance spectra in the vis-NIR range (500-900 nm) were 
scanned. The linear curve was fitted by the absorbance at peak of 680 nm and concentration. 
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Figure 3.17 Conjugation rate measurement 
The conjugation efficiency was calculated by scanning the ProCA1-affi342m-cy5.5 in 
HEPES buffer (10 mM, pH7.0) of a whole spectrum between 220-900nm. The protein concen-
tration was calculated by the Abs280. The dye concentration was calculated by Abs675. 
 
 
 
MS spectra and NMR were also used to verify the conjugation of NIR dye to the ProCA1-
affibody (Figure 3.17). Since Cy5.5 is a very sensitive dye and MRI is a relatively low sensitive 
technique which requires high amount of contrast agent, we label a small portion of ProCA1-
affi342 with Cy5.5 to produce non-saturated NIR imaging. 1D-NMR also confirmed that the dye 
was successfully conjugated to the ProCA1-affi342 by viewing the peak shifting (Figure 3.18). 
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Figure 3.18 MS spectra of free protein and conjugated protein 
MALDI-TOF mass spectrometry analyses the mixture after PEGylation with PEG40 
(2.4KDa) and fraction purified by ion-exchange FPLC. There were two major peaks in the PEGy-
lation mixture. Peak I was native ProCA1 with measured molecular weight of 11,192 KDa, peak 
II was ProCA1-affibody-Cy5.5 with measured molecular weight of 13,527 KDa. 
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Figure 3.19 NMR spectra of free protein and protein-dye complex 
About 100 µM of ProCA1-affi342 and ProCA1-affi342-cy5.5 complex were dissolved in 
10 mM Tris buffer (pH7.0). The NMR spectra at 600 MHz were obtained. 
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Chapter 4. CELLULAR TARGETING CAPABILITY ANALYSIS 
4.1 Introduction 
As the discussion in Chapter 1.7, in order to achieve molecular imaging, contrast agent 
should have very strong affinity to its biomarker. In addition, a strong selectivity over other re-
ceptors or non-cancer cells is also very important. Further, quantitative measurement of the 
biomarker level by the contrast agents is also important for the diagnosis and prognosis of the 
disease states. Moreover, to achieve molecular imaging of biomarkers by MRI, we also need to 
have enriched biomarkers. Since endocytosis especially receptor-mediated endocytosis was re-
ported to facilitate the enrichment of MRI contrast agents in the cancer cells [125].  
In this dissertation, we selected the suitable protein of peptide for tumor targeting. The 
cancer cell lines were also well considered for the ex vivo and in vivo research model. As men-
tioned in  Chapter 1.4, affibody is a Phage display library, several generations of affibody pro-
teins were screen out by targeting to the extracellular domain of biomarker HER2 (Figure 4.1). 
Two of them with high binding affinity to HER2 were selected in our research. The two affibody 
sequences, ZHER2:4 and ZHER2:342 together with wild type affibody were fused to ProCA1-CD2. 
These sequences were selected because ZHER2:4 is the commercial available affibody product. 
ZHER2:342 is the reported affibody which has highest binding affinity to HER2 [126]. Wild type affi-
body was also added to be a non-specific control. At the same time, cancer cell selection is also 
very important for the research. 
In Chapter 3, we reported our design, preparation, and characterization of the confor-
mation, biophysical properties like relaxivity and metal binding affinity of ProCA1-affi342 
against HER2 biomarker.  In this chapter, we will focus on evaluate the cell targeting capability 
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of the designed contrast using various methods such as western blotting, immunofluorescent 
staining and ELISA. Tumor cell lines with different HER2 expression levels were selected. The 
endocytosis capabilities of ProCA1-affi342 to accumulate in cancer cells were also investigated. 
These results comparisons between ProCA1-affi342 and other affibody series or PEGylated 
ProCA1-affi342m confirm the designing strategy and modification advantages. 
 
4.2 Results and Discussion 
4.2.1 Selection of cell lines 
We used three human cancer cell lines, AU565, SKOV-3 and MDA-MB-231. AU565 is a 
human breast cancer cell line, with HER2 expression level 1 x 106 HER2/cell. SKOV-3 is an ova-
rian cancer cell line with estimated 3 x 106 HER2/cell [127]. MBD-MDA-231 is a breast cancer 
cell line with modest HER2 levels (~3 x 104 HER2/cell) [128]. EMT-6 is a HER2 negative mouse 
breast cancer cell line. 
 
4.2.2 Monitoring cell targeting of Affibody variants using western blotting 
In order to select a proper affibody variant for HER2 targeting, three variants were com-
pared by using the western blotting. All the three variants: ProCA1-affi342, ProCA1-affi4 and 
ProCA1-affi WT were added into AU565 and EMT-6 cells respectively.  
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Table 6 HER2 expression level in various cancer cells 
Positive Cell Lines Negative Cell Lines Source 
Names HER2 Number Names HER2 Number  
AU565 1.0Χ106 MCF-7 2.0Χ104 
Human Breast Tumor SKBR-3 7.3Χ105 MDA-MB-231 1.8Χ104 
BT474 1.06Χ106   
SKOV-3 3.0Χ106   Human Ovarian Tumor 
MIAPaca-2 1.0Χ106 Panc-1 Under 2.0Χ103 Pancreatic Tumor 
NT5 1.0Χ106 EMT-6 Under 2.0Χ103 Mouse Mammary Tumor 
 
Two different concentrations 3 µM and 10 µM were used. After being treated with the 
proteins for 2 hr in 37 ˚C, the cells were lysed and the cell lysis was used for western blotting. 
The antibody against ProCA1-CD2 was used to detect the contrast agents. Figure 4.2 shows that 
in HER2 positive cell line AU565, the ProCA1-affi342 was retained most in the lysis, which 
means this variant binds most to the HER2 positive cell line. The second generation variant Pro-
CA1-affi4 and wild type also shows some non-specific binding. The cells without treatment were 
used as negative control. In the HER2 negative cell line EMT-6, all the three variants show some 
binding which may due to the non-specific attachment to the cell membrane. ProCA1-CD2 
without targeting sequences was also added to the cells for a negative control (Figure 4.1c).  
85 
 
 
Figure 4.1 Western blot of ProCA1-affi been retained in the cancer cells 
The cells were treated with different generations of ProCA1-affibody and the retention 
of the protein in the cell lysis was measured to calculate the binding capability. The AU565 cell 
with HER2 overexpression shows obvious binding to ProCA1-affi342. ProCA1-affi2-4 and Pro-
CA1-affi-WT also have some non-specific binding (A). In the HER2 negative cells EMT6. Only 
ProCA1-affi342 shows weaker binding (B). ProCA1-CD2 was used as negative control which also 
has some non-specific binding in both cell lines (C). 
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ELISA was further used to confirm the specific binding of ProCA1-affi342 to the HER2 
positive cell lines (Figure 4.3). ELISA is a method with more accurate quantitative analysis of 
protein and protein interactions. Equal number of SKOV-3 and MDA-MB-231 cells were cultured 
and treated with ProCA1-affi342 and ProCA1-342m respectively for 2 hr in 37 ˚C. After carefully 
washing with HBSS buffer, the cells were lysed and the lysis was used to coat the ELISA plates. 
Then the ProCA1-affi342 or ProCA1-affi342m retained in the will be detected by PAb-ProCA1-
CD2. The final absorbance read from ELISA was substrate from the absorbance of SKOV-3 cells 
with the one of MDA-MB-231 cells. The results show that the contrast agents can target to the 
HER2 positive cells lines. The PEGylated ProCA1-affi342 keeps the tumor binding capability. 
 
 
Figure 4.2 ELISA of ProCA1-affi342 
Indirect ELISA was used to measure the ProCA1-affi342 and ProCA1-affi342m binding to 
the cancer cells. Cell lysis of AU565 (HER2 positive) and EMT-6(HER2 negative) was used to coat 
the ELISA plate. Then the ProCA1-affi342 and ProCA1-342m was added and detected by primary 
antibody and secondary antibody with HRP conjugation. Finally, OPD was added to react with 
HRP and the Abs450 was read. The x axis is protein concentration. The y axis is the absorbance 
of AU565 substrates with EMT6. 
 
4.2.3 Immunofluorescent staining of cancer cells with ProCA1-affi 
We next examined whether the designed ProCA1-affi can target to cancer cells by cell 
binding analyses. Binding of the Gd-ProCA1-affi to the selected cells was first analyzed by im-
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muno-fluorescence staining using the polyclonal antibody against PEGylated parental protein 
ProCA1 (PAb-ProCA1). A substantial staining intensity of ProCA1-affi bound to AU565 cells was 
observed and increased as incubation times increased. In contrast, the EMT-6 cells demonstrat-
ed very weak staining (Figure 4.4). It was evident that the Gd3+ ProCA1-affi bound to the cell 
surface HER2 with a clear membrane staining pattern in AU565 cells at 4 °C (Figure 4.4). The 
wild type affibody variant, ProCA1-affi WT was also used to stain the cancer cells, Figure 4-5 
shows that the wild type variant can only non-specifically attach to the cell membrane. Howev-
er, binding of the Gd3+ proteins to the cells triggered receptor mediated internalization at 37 °C 
as demonstrated by the staining of the intracellular ProCA1-affi. The majority of the contrast 
agents entered the cells after 120 minutes incubation (Figure 4.6). The Gd3+ ProCA1-affi was 
stable after internalization at 120 minutes, indicating that the designed Gd3+ ProCA1-affi with-
stood protein degradation during and after endocytosis. The immunostaining results were con-
sistent with NIR fluorescence imaging results (Figure 4.7).  
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Figure 4.3 Immunostaining of HER2 on cell membrane.  
At 4  C̊, the HER2 positive (AU565) and negative (EMT-6) cancer cells were treated with 
ProCA1- affi and ProCA1 -affi-m respectively for 2 hours. The HER2 expressed on the cell mem-
brane of AU565 was revealed by the green color from the goat-anti-rabbit secondary antibody 
(Invitrogen) for self-generated rabbit antibody against ProCA1-affi-m. The blue color shows the 
nuclear staining. The imaging was taken under 40x objective in Zessis microscope. 
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Figure 4.4 Cell staining by ProCA1-affi WT 
When the tumor cells were stained by ProCA1-affi WT, both the AU565 with high HER2 
expression level and the HER2 negative EMT-6 got staining on the cell membrane. This indi-
cated that the wild type affibody only non-specifically binds to the cell membrane. The EMT-6 
cell without adding affibody was used as negative control. The imaging was taken under 40x 
objective in Zessis microscope. 
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Figure 4.5 Immunostaining for endocytosis studies.  
At 37  C̊, the cancer cells with HER2 positive (AU565) and negative (EMT-6) were treated 
with ProCA1 -affi and ProCA1 -affi-m respectively for 5 min and 2 hours. The immunefluores-
cence staining studies revealed that ProCA1- affi and ProCA1- affi-m bind to HER2 positive cell 
extensively and were largely relocated into the cytosol via endocytosis after 2 hours (green col-
or). The blue color shows the nuclear staining. At both 4 and 37 C̊, negative staining was ob-
tained in EMT-6 cells that lack HER2 expression. The imaging was taken under 40x objective in 
Zessis microscope. 
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Figure 4.6 NIR imaging of living cells.  
The living cells AU565 and SKOV-3 with overexpression of HER2 can be directly detected 
by ProCA1-affi342mCy5.5 which will generate NIR signals. 
 
 
 
4.2.4 Cancer cells treated by different amount of ProCA1-affibody demonstrate the quantit-
ative monitoring capability of designed MRI contrast agents 
In order to get quantitative results from in vivo data, ProCA1-affi342 has to be constant-
ly retained by cancer cells and get endocytosis. Figure 4.7 shows that in HER2 positive cell line 
AU565, ProCA1-affi342 can penetrate the cell membrane which makes the cell plasma been 
stained with FITC conjugated antibodies. On the other hand, the modified protein ProCA1-
affi342m can get endocytosis faster than the original ProCA1-affi342, which means the PEG re-
sidues facilitate the binding of proteins to cell membrane. The HER2 negative cell line EMT 6 
was stained for negative control. According to Table 3, cancer cell express different levels of 
HER2, in this dissertation, four cell lines have been measured by ELISA of the binding with Pro-
AU565 SKOV-3
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CA1-affi342. The ELISA results (Figure 4.8) show that the retained ProCA1-affi342 will be in-
creased as the incubation concentration increasing. The absorbance is highest in SKOV-3 indi-
cates that SKOV-3 has highest HER2 expression level, while EMT-6 is negative. 
 
Figure 4.7 Immuno staining of Cancer cells at various time points 
The cells were treated with ProCA1-affi342 and ProCA1-affi342m with different time 
length. In shorter time (5 min), the binding of ProCA1-affi342m to the HER2 positive cells 
AU565 had been observed. At longer incubation time (60 min), both ProCA1-affi342 and Pro-
CA1-affi342m can target to the AU565. Therefore, the modified ProCA1-affi342 with PEGylation 
can target to the cancer cells with HER2 overexpression in shorter time. However, the EMT-6 
negative cells also had some staining with ProCA1-affi342m treatment, which means ProCA1-
afi342m has more non-specificity also. 
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Figure 4.8 ELISA results to measure the binding to cancer cells 
In order to detect the expression level of HER2 in different cancer cells, all the cells were 
lysate for the ELISA. The cell lysis was diluted into four different concentrations and detected by 
ProCA1-affi342. SKOV-3 has highest expression level. EMT-6 is a HER2 negative cell line. 
 
 
4.2.5 Flowcytometry measures the constant binding of ProCA1-affi342 to cancer cells 
Flowcytometry is also another common way to quantitatively analyze the cell binding 
capability (Figure 4.9). The binding constant can be fitted by this assay. In this assay, the cells 
were incubated with ProCA1-affi342m for 2 hr to enable enough endocytosis. Then the cells 
were washed by HBSS buffer and stained by fluorescent conjugated antibody. After that, 
2.0×104 cancer cells were counted by Flowcytometre machine and the fluoresence was 
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measured. Figure 4.9 shows the binding constant of ProCA1-affi342. However, the binding 
cannot be well fitted by the Hill equation (Equation 2) either (Figure 4.10). This is probably due 
to the other molecules in the cell enviroment affecting the binding. In order to get the binding 
affinity between ProCA1-affi342 and cancer cells, larger number of cells needs to be measured 
to get a more statistc result and the measurement needs to be repeated multiple times. 
∆𝑆 = [𝑀]𝑛
𝐾𝑑
 𝑛+[𝑀]𝑛            (Equation 2) 
Besides the directly measurement of binding constant between ProCA1-affi342m, the 
binding was also measured by competitative assay. Commercial Affibody ZHER2:4 with FITC 
conjugated was incubated with the cells first. After 2 hr, the non-specific binding was washed 
and a series of concentration of ProCA1-affi342m was added. The fluoresence was measured 2 
hr later. Due to the competition of ProCA1-affi342 to ZHER2:4, the fluoresence value decreased as 
the increasing of ProCA1-affi342m concentraion. 
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Figure 4.9 Binding affinity measurements (A) and Curve fitting of the binding between 
ProCA1-affi342m and SKOV-3 cancer cells (B) 
The cells were treated by ProCA1-affi342 with different concentrations for 1 hr in 37 °C. 
Then the cells were washed and detected by FITC conjugated antibodies. (A) Shows the initial 
flow cytometry curve obtained. X-axis is the fluorescent intensity; y-axis is the counted cell 
numbers of been stained. (B) With the peak area and protein concentrations, the curve has 
been fitted. However, a binding affinity has not been derived from this curve which may due to 
the impurity of cell mixture. 
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Figure 4.10 Curve fitted by Hill equation 
Normalized data were fitted by Hill equation shown in the figure. M0 is the protein con-
centration, m1 is the dissociation constant (Kd) and m2 is the cooperate number. 
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Figure 4.11 Competative assay to measure the cell binding 
The cells were treated by both ProCA1-affi342 and ProCA1-affi4-FITC. The concentration 
of ProCA1-affi4-FITC is 2 pmol in stable. The concentration of ProCA1-affi342 range is from 0 to 
4 pmol. 
 
 
4.2.6 Generation of antibody against ProCA1-CD2-m 
Although there are commercial antibodies against CD2 protein, we mostly use PEGy-
lated contrast agents for our research. The detection sensitivity of commercial available antibo-
dies will be decreased due to the modification covers epitopes of the antibodies. Therefore, the 
polyclonal antibodies against PEGylated protein have been generated in our group. The purified 
ProCA1-CD2 with PEGylation was injected to New Zealand white rabbit at the concentration of 
5 mg/ml in HEPES buffer once every week for six weeks. The protein was mixed with adjuvants 
before injection, since adjuvants can stimulate the immune system to generate as much anti-
body as possible. The first time injection is called inoculation, which uses the complete adju-
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vant. Complete adjuvant is harmful to animal body which can only be allowed to use once dur-
ing the whole procedure (ICUCA protocol 7206). The non-complete adjuvant is used for the fol-
lowing injections, which are also called boosts. Rabbit blood starts to be collected after the 
third boost. The blood serum containing antibodies will be harvest after centrifuging. The activi-
ty of anti-serum was measured by western blotting. The same quantity of PEGylated ProCA1-
CD2 was loaded to each lane of SDS-PAGE gel. The anti-serum was diluted 2000 times and 5000 
times to be used. Pre-bleeding from the rabbit without injection of antigen was used as nega-
tive control. Figure A1 shows that the generated antibody has high specificity by identifying the 
PEGylated ProCA1-CD2 clearly even by 5000 times dilution.  
In order to use the generated anti-serum more sufficiently and keep the generated anti-
bodies for longer time, the antibody was extracted out from the serum and purified. The anti-
bodies were purified by precipitation methods. First, octanoic acid was added slowly with the 
amount of 28 µL/mL blood serum [129]. In this step, most of the lipids and other hydrophobic 
contents will be removed from the serum. Second, saturated ammonium sulfate was used to 
make the antibodies been precipitated. The precipitated antibody will be pure and can be dis-
solved in PBS buffer for long time storage (Figure 4.13).  
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Figure 4.12 Western blotting of anti0serum activity 
Lane 1 and 4: detected by pre-bleeding serum Lane2: detected by final bleeding with 
5000 times dilution Lane3: detected by final bleeding with 2000 times dilution Lane5: detected 
by anti-serum of ProCA1-affi342m. 
 
 
  
Figure 4.13 Purified antibodies from anti-serum 
Lane 1-6: antibodies purified from different anti-serums. The antibodies in non-reduced 
gel show a molecular weight of 150 KDa. 
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4.2.7 Quantitative analysis of MRI signals in cancer cells 
MRI is a technique with high resolution which makes quantitative analysis possible in vi-
vo. Here we measured the retention of Gd-ProCA1-affi342m in cancer cells under 7T MRI ma-
chine. The cancer cells were incubated with a series concentration of ProCA1-affi342m. The im-
ages were scanned with two pulse sequence. In the gradient echo, we can identify the gradual 
changes of MRI intensity as the concentration change of ProCAs. In the spin echo, the differ-
ence is not visible (Figure 4.14), which indicates than this pulse sequence is not optimized for 
your contrast agents. 
 
Figure 4.14 The HER2 positive cells SKOV-3 can be imaged under MRI after incubated 
with various concentrations of contrast agents. 
The cells were treated with Gd-ProCA1-affi342 or Gd-ProCA22-affi342 with different 
concentrations for 1 hr and then washed. The image indicates the specific binding of contrast 
agents to SKOV-3, the HER2 positive cells. 
 
 
4.2.8 Cell binding was analyzed by measuring retention of 153Gd cheleted with ProCA1-
affi342 
Binding of the Gd3+ ProCA1-affibody to the two testing cell lines was further analyzed by 
quantification of cell bound Gd3+ by γ-counting the trace of isotope 153Gd3+ in the Gd3+ ProCA1-
affibody complexes (Fig. 4.15). The results supported our immuno-analyses that Gd3+ ProCA1-
affibody was retained 3-4 folds greater in HER2 positive AU565 cells than HER2 negative EMT-6 
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cells (Fig. 4.16). Measuring the amount of bound Gd3+ from γ-counting revealed that the Gd3+ 
ions were bound to cells at ~ 0.1 fmole Gd/cell. Under assumption that 1x107 cells make a vo-
lume of 50 – 100 µL, this binding capacity led to the accumulation of Gd3+ at 10 – 20 µM in the 
cell pellets. This local concentration is sufficient to produce strong MRI contrast, especially with 
the high relaxivity protein contrast agent reported here. 
 
 
 
Figure 4.15 Different concentrations of ProCA1-affi342 been retained in the cancer cells 
by radioactive assay.  
By treated the cancer cells with various concentrations of 153Gd-ProCA1-affi342, the HER2 pos-
itive cell line AU565 shows constant binding of the proteins to cells, however, in the HER2 nega-
tive cell line, the binding shows non-specifically. 
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Figure 4.16 Radioactive assay to measure the cell binding of ProCA1-affibody.  
153GdCl3, and
153Gd loaded ProCA1 -affi and ProCA1-affi-m were incubated with cultured 
cancer cells for 2 hours. After careful washing, the radioactive signaling in the cell pellets was 
measured using γ-counter. The retention of ProCA1-CD2-affi or ProCA1-CD2-affi-m with Gd3+ in 
HER2 positive cells (AU565) was ~3-4 folds greater than that in the HER2 negative cells (EMT-6) 
and non-specific uptake in 153GdCl3 treated cells. 
 
4.2.9 Summary and future work 
In this chapter, various binding assays have been used to measure the binding of Gd3+ 
with ProCA1-affi342 and ProCA1-affi342 with cancer cells of high expression HER2. The results 
show that the fusion of affibody342 does not affect the metal binding site, which indicates a 
similar metal binding affinity (Kd=1.86 nM) as native protein ProCA1-CD2. Cell binding assays 
demonstrate that ProCA1-affi342 can specifically target to the cancer cells with high expression 
of HER2. We also tried initial quantitative analysis of the cell binding assay to obtain the binding 
affinity of ProCA1-affi342 with HER2 in cancer cells. However, the fitting of the affinity is not 
reliable (Figure 4.9-10). This may due to the non-homogenous of the cell lysate solution and 
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non-stable cell status. Further analysis using Biacore, relaxometer or flow cytometer with high-
er numbers of cells to eliminate or decrease the affecting parameters will be applied. 
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Chapter 5. ESTBLISHING TUMOR MODELS AND MOLECULAR IMAGING OF HER2 IN MOUSE 
BY MRI AND NIR AND FURTHER ANALYSIS BY HISTOLOGY ASSAYS 
5.1 Introduction 
Molecular imaging specifically probes the molecular abnormalities of diseases to allow 
earlier detection, monitoring of disease progression, and molecular assessment of treatments 
[130]. Molecular imaging using the modality of magnetic resonance imaging (MRI) has signifi-
cant advantages in pre-clinical research and clinical diagnosis and prognosis as MRI offers supe-
rior spatial resolution without depth limitation, exquisite soft tissue contrast,  clinical availabili-
ty, while avoiding ionizing radiation [131]. However, many applications of MRI rely on the ad-
ministration of contrast agents to amplify the contrast of the interested regions to obtain both 
sensitivity and specificity [132]. Developing contrast agents that can be specifically targeted to 
various biomarkers allowing real-time imaging of biological events at the molecular level will 
have great clinical importance [133-135]. To achieve molecular imaging by MRI, especially to 
quantitatively monitor the expression level of the disease biomarkers, it is essential to develop 
contrast agents with high relaxivity, target capability, optimized pharmacokinetics, tissue pene-
tration and low or no toxicity [136]. 
As discussed in Chapter 1.2, human epidermal growth factor receptor (EGFR) type 2 
(HER2/neu) is a cell surface receptor of the EGF family that is overexpressed in breast, ovarian, 
urinary bladder and many other carcinomas.  In the case of breast cancer, HER2 overexpression 
is typically associated with younger patients and generally poor prognoses with substantially 
higher probabilities of relapse after treatment [45, 48]. In addition, the HER2 mediated recogni-
tion system has been widely employed as a drug target for anti-cancer therapies. Unfortunate-
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ly, current diagnosis of HER-2 positive tumor relies mostly on the use of fine needle biopsies 
with subsequent immunohistochemistry (IHC) analysis and/or fluorescent in situ hybridization 
(FISH).  These methods suffer from several drawbacks including sampling errors, misinterpreta-
tion due to lack of quantization, and discordance between primary tumors and metastases. 
Thus, assessment of HER2/neu levels by non-invasive MR imaging will provide a tremendous 
tool for cancer diagnosis/prognosis, design of treatment strategies, and monitoring the effec-
tiveness of the treatment. 
In order to measure the in vivo function of ProCA1-affi342, suitable tumor model was 
selected. In this chapter, there are mainly two tumor models being discussed. One is subcuta-
neous model, which the cancer cells were injected under the surface skin [62]. SKOV-3 and 
MDA-MB-231 cell lines were selected because they have moderate tumorigenicity and well dif-
ferential shape. The moderate means the tumor growing speed of these cell lines in nude mice 
is around 4-8 weeks which is easy to control and monitor [137]. Since we inoculate two differ-
ent cell lines on each flank of the nude mouse, the selected cell lines should have similar tumo-
rigenicity. Therefore, the cell lines of AU565 with rare tumorigenicity and EMT-6 which can 
generate tumors within one week were not selected for our research. Another tumor model is 
the orthotopic model which can mimic the real tumor situation by injecting tumor cells in the 
original sites, for example, the breast cancer cell line MCD-10DCIS will be injected to the mam-
mary sites of the nude mice. 
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5.2 Results and discussion 
5.2.1 Cell preparation for xenograft tumor model 
The SKOV-3 and MDA-MB-231 cells were cultured and passaged in Coy’s 5A and DMEM 
medium respectively. Cells were scraped from the flask and suspended in HEPES (10 mM, 
pH7.2). Then the cells will be washed with HEPES buffer for three times and counted. Finally the 
cells will be diluted in to 5x106 /100 µL medium. The injection medium is 50% HEPES buffer with 
50% percent matrix gel (BD bioscience). Each spot on the mouse flank will be injected with 100 
µL of the cells. 
 
5.2.2 MRI on xenograft model indicates the specific targeting of ProCA1-affibody 
We then tested whether our designed contrast agent would result in MRI contrast en-
hancement in xenograft models of these two human cancer cell lines. The SKOV-3 tumor with a 
high HER2 expression was subcutaneously implanted in the right flank, while the MBD-MDA-
231 with a low HER2 expression was implanted in the left flank of the same mouse for direct 
comparison (Figure 5.1). The contrast agent Gd3+ ProCA1-affi-m at concentration of 3 mM (10 
fold lower than clinically-approved contrast agent DTPA) was administrated via the tail vein (80 
µL). Pre- and post-contrast MRI were collected at different time points using T1 and T2 
weighted fast spin echo or T1 weighted gradient echo sequences. After 3 hr, HER2 positive tu-
mor exhibited significant contrast enhancement.  Strong contrast enhancement was observed 
in the SKOV-3 tumor 24 hours after injection, while there were no significant changes in con-
trast in the MBD-MDA-231 tumor (Figure 5.2 and Figure 5.3). Such MRI contrast enhancement 
107 
was decreased after 24 hrs post injection.  In parallel, the mice were imaged using an optical 
animal imaging system (Figure 5.1).  Consistent with MR imaging, we observed a strong NIR 
light emission from the SKOV-3 tumor at 24-hour post-administration of the contrast agent, 
however, the NIR intensities at the MBD-MDA-231 tumor site were much less than that of the 
SKOV-3 tumor (Figure 5.4).  
 
 
 
 
Figure 5.1 NIR imaging on Xenografted mouse.  
NIR fluorescence imaging (Kodak 8000) revealed that ProCA1-Affi is able to target to the 
HER2 positive tumor (SKOV-3, right) 24 hr after injection from tail vein. No significant near IR 
signal was detected in the HER2 negative tumor (MDA-MB-231, left). 
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Figure 5.2 MRI of Xenografted mouse with Fast Spin Echo.  
Fast spin echo transversal MR images collected prior to injection and at various time 
points post injection of 3.0 mM of ProCA1-affi-m in HEPES saline via tail vein. The MRI signal on 
the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and 
reaches maximum enhancement at 24 hours post injection. The slight differences in MRI signals 
result from the use of different pulse sequences for imaging. 
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Figure 5.3 MRI of Xenografted mouse with Gradient Echo.  
Gradient echo transversal MR images collected prior to injection and at various time 
points post injection of 3.0 mM of ProCA1-affi-m  in HEPES saline via tail vein. The MRI signal on 
the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and 
reaches maximum enhancement at 24 hours post injection. The slight differences in MRI signals 
result from the use of different pulse sequences for imaging. 
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5.2.3 NIR imaging shows relative distribution of ProCA1-affibody in various mouse organs 
To further analyze the HER2 targeting properties of the protein contrast agent, tumors 
and organs from the imaged mice were collected 48 hours after administration of the agent 
(Figure 5.4). The organs and tumors were imaged using optical animal imaging. It was clear that 
there were very high levels of accumulation of Cy5.5 in the liver, kidneys, and the SKOV-3 tu-
mor. There were medium levels of the NIR dye at lung. In comparison, the level of Cy5.5 at the 
MBD-MDA-231 tumor was quite low (Figure 5.4). The results strongly suggested that our pro-
tein contrast agent led to the HER2 specific MR image enhancement.  
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Figure 5.4 NIR imaging of mouse organs.  
NIR images of the dissected mouse organs. General bio-distribution was obtained based 
on the NIR signal and western blot assay. The ProCA1-affi-m mainly distributed in the positive 
tumor, liver and kidney. 
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5.2.4 Immunofluorescent staining of frozen tissue slides can demonstrate the tissue pene-
tration of ProCA1-affibody 
To further verify the contrast agent targeted to the HER2 positive tumor, we carried out 
immunohistochemistry (IHC) staining using the antibody PAbPGCA1 with tissue slides made 
from the tumor samples collected from the imaged mice as well as selected organs. The strong-
est staining was observed with liver and the SKOV-3 tumor tissue slides (Figure 5.5). Close ex-
amination of the staining patterns of the tumor slides revealed distribution of the designed pro-
tein both inside and outside the cancer cells with substantial stronger staining inside the cancer 
cells, indicating internalization of the protein contrast agent. This staining pattern provided a 
strong support for the cancer cell targeting by the contrast agent. The kidney slides also gave 
strong immunostaining consistent with the NIR imaging finding.  Interestingly, the areas near 
proximal tubes showed the strongest staining (Figure 5.5), suggesting that the protein contrast 
agent may be secreted through the kidney. This is consistent with observations that there were 
good levels of both Gd3+ (by γ-counting of 153Gd3+) and the protein (by NIR fluorescence) in the 
urine of mice that were injected with the contrast agent. Immunostaining of tissue sections 
from MBD-MDA-231 tumor revealed very weak staining (Figure 5.5). 
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Figure 5.5 IHC staining on mouse tissues for biodistribution studies.  
Immune histology fluorescent (IHF) staining was applied to various tissue slides stained 
by antibody against ProCA1-affi-m (red), Blood vessels biomarker CD31 (green), and nucleus 
DAPI (blue). The slides stained without primary antibody were used as blank control. 
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5.2.5 MRI blocking experiment further confirmed the tumor targeting 
To further verify the HER2 specific MRI contrast enhancement, we carried out a compe-
tition assay based on the assumption that if our protein contrast agent targeted HER2 and led 
to HER2 specific MRI contrast enhancement, affibody alone would be a strong competitor for 
the binding to the cell surface HER2 and consequently block the binding by our designed pro-
tein.  Nude mice that carried SKOV-3 tumors were pre-injected with buffer saline or 3 mM of 
HER2 affibody ZHER2-342 labeled with Cy5.5 twice at 12 hr and 2 hr. Gd
3+ ProCA1-affi-m (80 µL) at 
a concentration of 3 mM was subsequently administrated to the mice by intravenous injection. 
The mice were then scanned at a 4.7 T MRI scanner via the same procedures. Our results dem-
onstrated that the MRI contrast enhancements were not observed at the SKOV-3 tumor site in 
the mice that received HER2 affibody labeled with Cy5.5, while the contrast enhancements in 
the liver and kidney in the same mouse were not affected by the administration of HER2 affibo-
dy (Figure 5.5). NIR imaging did exhibit high intensity in the tumor, which indicates that the af-
fibody binds to the positive tumor and blocks the binding of MRI contrast agents. Conversely, 
the administration of the saline prior to injection of the designed protein contrast agent did not 
block the MRI contrast enhancement (Figure 5.6). The results with HER2 affibody blocking 
strongly support our conclusion that the MRI contrast enhancement from administration of 
Gd3+ ProCA1-affi-m is HER2 specific.  
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Figure 5.6 Magnetic resonance images and image intensities of the mouse tumor pre-
blocked by affibody ZHER2:342.  
In the blocking experiment, the mice were born with SKOV-3 tumor on the right back. 
The affibody ZHER342 of 3 mM in HEPES buffer was intravenous injected into the mice for 12 hr 
and 4 hr before taking MR images [138]. The mice were also scanned at various time points of 4 
hr and 24 hr.  
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5.2.6 Advantages of ProCA1-affibody to antibodies in tumor targeting 
Since antibodies have been widely used in drug and imaging probe deliveries in molecu-
lar marker targeted applications [133, 135] we further compared the immunofluorescence 
staining patterns of our designed protein agent and a commercially available HER2 antibody. To 
this end, ProCA1-affi-m (10 mg/kg) or the HER2 antibody (10 mg/kg) was administrated in the 
SKOV-3 tumor bearing nude mice via tail vein. 24 hours post injection, tissue sections were pre-
pared from the tumor tissue, and the sections were analyzed either by immunofluorescence 
staining using the antibody PAbPGCA1 (for analyses of ProCA1-affi) or direct application of the 
second antibody against rabbit IgG to detect the bound anti-HER2 antibody. The tissue sections 
from both cases were also co-stained with the antibody against CD31. At 24 hours post injec-
tion, the anti-HER2 antibody was mainly concentrated around endothelial cells as revealed by 
co-localization with anti-CD31 staining. This is in sharp contrast to the even distribution of Pro-
CA1-affi-m in the entire tumor (Figure 5.5). The distributions of the anti-HER2 antibody to the 
area distant from endothelial cells were clearly quite reduced as demonstrated by weak immu-
nostaining in the areas where there was no CD31 staining (Figure 5.8). We further examined the 
distribution of our protein agent and the anti-HER2 antibody at an early time point. Tissue sec-
tions from the SKOV-3 tumors were prepared 4 hours after administration of ProCA1-affi-m or 
the anti-HER2 antibody.  Interestingly, while the ProCA1-affi-m was largely concentrated with 
the CD31 staining in the tumor, the anti-HER2 antibody was not detectable by the immunofluo-
rescence staining analyses. (Figure 5.8). The results strongly suggested that our designed pro-
tein agent was able to cross the endothelial and distribute to the deep tumor tissue a few hours 
after administration while the large size of antibody (~160 kDa) significantly hindered endo-
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thelial and tissue penetration.  Consistent with the 50% reduction of MRI intensity at the tumor 
site by affibody blocking shown in Figure 5.6, the fluorescence immunostaining at the same tu-
mor site also exhibited about 60-90 ± 20% decrease in intensity (Figure 5.8). Taken together, 
our developed MRI contrast agent exhibits a potential capability for future quantitative analysis 
of the biomarker in vivo. 
A very crucial requirement for application of an agent for delivery of both drugs and im-
aging probes to target a disease marker is the capability of the agent to cross the endothelial 
barrier and to allow for proper tissue penetration and distribution. In particular, even distribu-
tion of an imaging probe throughout the entire cancer site is vitally important for quantitative 
or semi-quantitative assessment of a particular cancer marker. HER2 is evenly expressed across 
the entire SKOV-3 tumor as revealed by immunostaining using a commercially available antibo-
dy (Sigma). Co-staining using an antibody against the endothelial marker CD31 revealed that 
the distribution of HER2 is not dependent on the distance to the vessels (Figure 5.9).  
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Figure 5.7 Direct staining with SKOV-3 tumors.  
Immunofluorescent histology of tumor tissue (Xenograft SKOV-3 model) stained by 
HER2 antibody and ProCA1-affi324-m 
 
 
Presumably, the proper size of ProCA1-affi-m provides a great advantage to target the 
molecular markers. To evaluate the tissue distribution and endothelial penetration of our de-
signed protein contrast agent, we conducted immunofluorescence staining of the designed pro-
tein in the tissue sections prepared from various organs after systematic administration of the 
protein using the antibody PAbPGCA1. The tissue sections were also co-stained with the anti-
body against CD31. It was clear that high levels of ProCA1-affi-m were targeted to the SKOV-3 
tumor at 24 hours post injection, and the protein was distributed in the entire tumor evenly 
since its intensity is not changed significantly upon increasing the distance from vessel staining 
CD31 to 40 µm (Figure 5.7). The results from the immunofluorescence staining suggested that 
the designed protein contrast agent had excellent endothelial and tumor tissue penetration, 
and was not simply trapped in the blood in the micro-vasculature of the tumor tissue. 
HER2  antibody                                    ProCA1-affi-m
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Figure 5.8 Compare the tissue penetration with HER2 antibody by IHC. 
 Immune histology fluorescent (IHF) staining was applied to various tissue slides stained 
by antibody against ProCA1-affi-m (red), Blood vessels biomarker CD31 (green), and nucleus 
DAPI (blue). 
 
Red: ProCA1-affi-m or HER2 antibody
Green: CD31
Blue: DAPI
Positive tumor stained 
with HER2 antibody
Positive tumor stained 
with ProCA1-affi-m
Positive tumor stained 
with HER2 antibody
Positive tumor stained 
with ProCA1-affi-m
Blood Vessel
Blood Vessel
24 hr 24 hr
4 hr 4 hr
120 
 
Figure 5.9 The tissue penetration properties of ProCA1 –affi-m were compared with an-
tibody by IHF staining.  
The tumor slides are from the mice which were dissected 24 hr and 4 hr after injection 
with ProCA1-affi-m or antibody. After 4 hr, ProCA1 –affi-m began to distribute around the blood 
vessel. The antibody had not been detected in the tumor tissue. After 24 hr, ProCA1-CD2-affi 
was evenly distributed in the tumor tissue and the antibody mainly concentrated around the 
blood vessel. 
 
HER2 has been validated as a very important prognosis and treatment marker for cancer 
patients expressing HER2, especially in the case of breast cancer. Development of Herceptin 
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(trastuzumab) and other HER2 targeting drugs has resulted in significant improvement in pa-
tient survival. Unfortunately, current methods for determination of HER2 status rely on invasive 
biopsy coupled with IHC using a qualitative scoring system [139]. These methods suffer from 
both high false positive and false negative results, and large discordance in detection of HER2 
expression in primary tumors and metastases due to heterogeneity in tissue sampling.  These 
methods also cannot detect HER2 expression levels and patterns in the entire cancer site. Ac-
cording to a recent study by Philips et al., one in five HER2 clinical tests provided incorrect re-
sults[140].  Therefore, there is a great need to develop MRI contrast agents with specificity and 
sensitivity for HER2 imaging [141]. 
 
5.3 Conclusion 
In this present study, we demonstrate the success in molecular imaging of HER2 by de-
veloping a novel class of multiple modality contrast agent. To our knowledge, there is no pre-
vious report of effective imaging of HER2 expression cancer in vivo by noninvasive MRI with de-
sirable tissue penetration and using only a single injection. Our approach in designing protein-
based molecular imaging contrast agent differs greatly from previous reported studies in sever-
al aspects and represents a significant advance in molecular imaging by MRI. First, high relaxivi-
ty value in both T1 and T2 achieved by designing a Gd3+ binding site into a stable scaffold pro-
tein [142] allows for increased sensitivity in the detection of disease markers by MRI. Our 
achievement of MR imaging in animal with 100-fold lower dose usage than clinically used non-
targeting agent DTPA is also likely due to improved pharmokinetic properties such as retention 
time and biodistribution. Such significant improvements in in vivo dosage efficiency will poten-
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tially reduce potential Gd3+ toxicity risks, such as NSF (Nephrogenic Systemic Fibrosis). Second, 
the relatively small molecular size of the designed agent provides a unique opportunity to tar-
get the imaging probe to the molecular marker in the entire tumor mass. This property is of vi-
tal importance, especially for quantitative assessment of the molecular marker based on the 
imaging results. Several approaches have been employed to develop targeted MRI contrast 
agents [134-135, 143-149]. To increase contrast effects, high pay load contrast molecules were 
created by either encapsulating a large number of Gd-DTPA, conjugating multiple contrast 
agents such as polylysine-Gd-DTPA (PAMAM) [150], or using supermagnetic iron oxide nanopar-
ticles [107, 151]. The antibody approach was widely utilized as the targeting moiety either di-
rectly conjugated with high payload contrast agent or elegantly applied in multiple steps to pre-
label the tumor as a biotin-labeled antibody[152]. These pioneering studies demonstrated the 
feasibility of the targeting approach; however, the large size of the antibody-conjugated imag-
ing probes is likely to severely limit the endothelial penetration and even-distribution of the 
probes in the whole tumor (Figure 5.7). On the other hand, our contrast agent exhibits endo-
thelial penetration capabilities and an excellent distribution in the entire cancer mass as re-
vealed by its adequate distribution near the blood vessel four hour after administration, and 
the nearly-uniform distribution observed 24 hours post injection. One potential application of 
our developed MRI contrast agent is for quantitatively or semi-quantitatively assessing the 
HER2 levels in the entire tumor site using MR imaging, which is impossible with any current me-
thods. Since HER2 is overexpressed in a large percentage of breast, ovarian, gastric, urinary 
bladder and a number of other carcinomas, the developed contrast agents may be beneficial 
for imaging of HER2 in several types of cancer. In vivo real time monitoring of the changes in 
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HER2 expression levels and patterns will provide vital information for evaluation of the efficacy 
of drug treatments and for designing further strategies for cancer treatments.  
Based on the results on the animal model studies, we can also have the model for dy-
namic study. Since the protein in the small animals in dynamic circulation relies on different cell 
types [153], only the orthotopic tumor model can be applied to fulfill the requirements of dy-
namic situation [154]. In the future research, we will select the cell lines for orthotopic model 
with both breast and ovarian cancers. 
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Chapter 6. BIODISTRIBUTION AND PHARMOKINETIC STUDY OF DEVELOPED CONTRAST 
AGENTS 
6.1 Introduction 
Biodistribution is the process of monitoring where a compound or reagent spread in an 
animal body [155]. It also includes the kinetic changes of reagents in bloods which is called 
blood retention or circulation [156]. The secretion time is also dependent on biodistribution. 
For example, the gadolinium distributing to the bone may have long term retention. The biodi-
stribution of a molecule in vivo is dependent on several factors. Molecular weight first defines 
where a molecule will travel to. Small molecules like metals less than 5 KDa tends to distribute 
to liver [157]. Macro molecules tend to concentrate in spleen. The structure and surface charge 
will also define the distribution of specific molecules. 
Several imaging methods such as NIR fluorescence and PET have been applied in mole-
cular imaging for disease biomarkers for expression level determination. Antibodies are com-
monly used to target to the biomarkers. While these imaging techniques are highly sensitive, 
which suffer from two major problems:  lack of spatial imaging resolution, and limited tumor 
penetration due to the large size of the antibodies (~150 KDa). Thus, there is an urgent need for 
the development of a non-invasive imaging method with the capability to quantitatively deter-
mine the expression level and spatial distribution of biomarkers [34]. 
As discussed in Chapter 1.6 for the criteria of MRI contrast agents, in order to achieve 
MRI contrast enhancement, as a blood pool contrast agent, it should have long retention time. 
For achievement of molecular imaging, enough circulation time for targeting is needed. Howev-
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er, too long time may cause toxicity by heavy metals [158]. Current small molecules do not have 
good retention time with a half life time less than 5 minutes [159]. 
  In this chapter, we are going measure the biodistribution and metabolism by radioac-
tive assay and ICP-OES. By comparing with the biodistribution of non-targeted and targeted 
reagents, pegylation and non pegylation, the modified protein demonstrate long circulation 
time and better distribution. 
Current methods for determination of disease state largely rely on invasive biopsy 
coupled with a qualitative scoring system such as Immunohistochemistry (IHC) to measure the 
biomarker expressions such as PSA and HER2 receptors on the cell surface. Fluorescence in situ 
hybridization (FISH) was also used to detect gene amplification by measuring the number of 
copies of the HER2 gene in the nuclei of tumor cells[139, 160-161]. These methods cannot 
detect biomarker expression levels and patterns in the entire tumor especially in quantitative 
level. Therefore, incorrect results on HER2/Neu clinical tests were observed in one of five breast 
cancer patients [140].  
As one of the leading diagnostic techniques in clinical and preclinical settings,[54, 162-
163] MRI has the unique advantages of high resolution in capturing the 3-dimensional images 
with good body depth and without ionized radiation[164-166]. In this dissertation, we devel-
oped a targeted contrast agent to HER2 and established a quantitative analysis method in cell 
level. Biodistribution was also studied to calculate the retention of contrast agent in various or-
gans.  
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6.2 Results and discussion 
 
6.2.1 Distribution calculation by NIR signals in different mouse organs 
Besides quantitative analysis in cell level, we also calculated the biodistribution of our 
contrast agents using various methods. Since our dual labeled ProCA1-affi342m is also conju-
gated with NIR, once the mouse organs were dissected out from mouse body two days after 
injection, the NIR signal will be less affected by tissue depth. We can draw some quantitative 
conclusions. From Figure 6.1, we can see out contrast agents mainly stays in positive tumor and 
kidneys. Liver and negative tumor also had some retention. However, there was not so much 
contrast agents remaining in the muscle and lung. Figure 6.2 is a scale bar calculated from the 
integral intensity from Figure 6.1. Western blotting (Figure 6.3) of tissue extract and IHC of fro-
zen tissue slides (Figure 6.4) were also measured to see the biodistribution. These results are 
consistent with the NIR image data.  Based on these results, we can conclude that the ProCA1-
affi342m can still be detected in primary organs after two days of injection. Since large mole-
cules tends to filtered by kidneys, and NIR monitors the signal from the Cy5.5 dye which linked 
to the C-terminal of ProCA-affi342m, kidneys have relatively higher intensity than other organs. 
Muscle has little blood circulation which makes it completely dark without contrast agents re-
tention and been referred as negative control.  
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Figure 6.1 Biodistribution demostrated by NIR imaging 
The contrast agent concentrates in the positive site. The liver, kidneys are also the pri-
mary organs to accumulate contrast agents. 
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Figure 6.2 Average intensity of each organ by NIR measurement 
 
Figure 6.3 Western blotting of quantitative analysis of distribution 
The primary organs after MRI have been dissected and lysate. The lysis was detected by 
western blotting to estimate how much protein has been retained by each organ. 
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Figure 6.4 Biodistribution demostrated by IHC 
Primary organs were also embedded in paraffin and detected by PAb-ProCA1 for IHC to 
measure the general distribution of ProCA1-affi342m to each organ. 
 
 
6.2.2 Bio-distribution and blood retention by 153Gd assay 
Before measuring the biodistribution with radioactive assay, the general blood retention 
of ProCA1-CD2 had been measured by western blotting (Fgure 6.5). Two different concentra-
tions of ProCA1-CD2 had been injected into the CD1 mice of 100 µL with tail vein injection. Af-
ter different time points of 5 min to 4 hr, mice blood was taken from tail drop or eye ball bleed-
ing. The blood serum was measure by western blotting of the retention of ProCA1-CD2. Even 
after 4 hr, ProCA1-CD2 still had some retention in mouse blood without degradation.  
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Figure 6.5 Western blotting of blood retention 
The mice have been injected with 200 µM (up) and 500 µM (bottom) of ProCA1-CD2 respective-
ly. The concentration of ProCA1-CD2 in blood has decreased from 5 min to 4 hr.  
 
 
The previous measurements are based on the distribution of ProCA1-affi342m, because 
the protease cleavage and disassociation always exist in animal blood circulation, the distribu-
tion of Gd3+ was also measured by radioactive assay (Figure 6.6) or ICP-OES (Table 8). From Ta-
ble 7, we can see free Gd circulates mostly to spleen and liver, while Gd-ProCA1-affi342m circu-
lates more to the lung and liver. Figure 6.7 summarizes the distribution of contrast agents with 
different modification.  Most of the GdCl3 and non-modified proteins stays in the liver. The 
modified protein stays more in lung and liver. These results indicate that there are some disas-
200 µM ProCA1-
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500 µM ProCA1-
CD2 injected
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sociation which led the small molecules circulates to liver. Based on the blood circulation dia-
gram (Figure 6.7),  the modification of contrast agents largely increased the blood circulation 
time. 
 
 
Figure 6.6 Bio-distribution of ProCA1-affi by 153Gd radioactive assay.  
Injected GdCl3, 100 µM, 100 µL, via tail vein. The accumulation of 
153Gd was measured 
after 12 hr injection 
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Table 7 Biodistribution of Radioactive assay in CD1 mice 
 
 
 
 
 
 
 
Figure 6.7 Blood circulation of ProCA1 series contrast agents 
The mice were injected with 153Gd-ProCA1 series proteins. The radioactivity of the blood 
samples collected at different time points were measured. The ProCA1-CD2 with 40 units of 
PEGylation size has longest circulation time.  
 
 
GdCl3/1 GdCl3/2 CA-1/1 CA-1/2 CA-2/1 CA-2/2 CA1-P40/1 CA1-P40/2
Blood 0.8 0.9 1.5 2.4 2.2 3.0 2.7 2.5
Heart 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.1
Liver 63.3 64.6 68.4 63.9 75.4 72.2 38.1 27.8
Spleen 8.7 9.4 5.8 7.4 4.1 5.0 2.2 1.3
Lung 1.0 1.1 0.6 2.5 0.6 1.0 26.5 47.0
Kidney 1.6 1.5 1.4 1.8 1.3 1.3 1.9 0.9
Colon 4.6 1.0 3.4 2.0 1.6 1.5 2.0 1.0
Tail 1.6 3.7 1.5 1.7 0.9 1.7 1.6 0.9
Feces 0.9 0.7 0.2 0.2 0.3 0.4 2.3 0.9
Urine 1.5 1.2 0.3 0.3 0.2 0.2 1.6 0.6
Carcass 16.7 15.5 16.7 17.6 13.3 13.5 20.9 11.4
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6.2.3 Bio-distribution with ICP-OES 
As described in Chapter 2.0, the radioactive assay is a very sensitive technique to moni-
tor the Gd distribution. ICP-OES which can measure the total metal concentration is another 
method to measure the Gd distribution. All the mouse organs were dissolved in concentrated 
Nitric Acid overnight. Small liquid drop will be formed after all the organs being dissolved. The 
liquid drop was diluted with 2% Nitric Acid based on the original weight of each organ. Then the 
total Gd3+ concentration will be measured by the ICP-OES. Table 6 listed the percentage of total 
Gd3+ injection in each organ. Since GdCl3 circulates fast in animal body, it may be secreted out 
of the body within 5 min. Therefore, the mouse was sacrificed right after being injected with 
GdCl3. For the protein contrast agents, different time points have been measured. It shows that 
in shorter time, most of the contrast agents stay in the liver and lung, however, after one day, 
half of the reagents secreted out of the liver and the tumor accumulate more up to 7.59% of 
the total injection. After two days, the lung still retains more than 30% of the contrast agents. 
Correlated with our MRI data, the tumor receives highest signal after one day injection of Pro-
CA1-affi342m. Liver and lung are the two organs accumulate most of the ProCA1-affi342m. Fur-
ther optimized modification may be needed to make more protein contrast agents target to 
tumor.  
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Table 8 Bio-distribution of ProCA1-affi-m was measured by ICP-OES at various time points 
 
 
The distribution of different contrast agents are also compared especially the different 
distribution between PEGylated and non-PEGylated ProCA1-affi342. Table 9 shows the percen-
tage of total after one day of injection. Without PEGylation, most of the contrast agent goes to 
spleen instead of lung, similar like free GdCl3. We may conclude that PEGylation causes the con-
trast agents move from spleen to lung. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GdCl3 ProCA1-affi-
P40 (4 hr)
ProCA1-affi-
P40  (24 hr)
ProCA1-affi-
P40 (>2 d)
Heart 0.8 0.6 0.4 0.2
Liver 35.5±2.1 36.8±1.7 18.5±2.8 17.9±3.4
Spleen 50.3±4.5 22.9±2.6 5.0±1.9 13.4±3.2
Lung 3.8±0.1 38.7±3.6 39.4±4.5 30.6±5.7
Kidney 2.6±0.1 3.9±1.1 3.1±0.9 4.6±0.7
Muscle 0.2 0.4 0.1 0.6
Tumor 1.1±0.1 2.1±0.1 7.5 3.7±0.8
Unit: %total injection
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Table 9 Bio-distribution of MRI contrast agents was measured by ICP-OES to optimize 
the modification condition 
 
 
 
 
 
 
 
 
 
 
GdCl3 ProCA1-CD2 ProCA2-P40 ProCA1-affi-
P40 
Heart 0.8 0.6 0.9 0.4
Liver 35.5±2.1 38.1±3.4 22.6±2.1 18.5±2.8
Spleen 50.3±4.5 45.4±2.6 28.2±3.4 5.0±1.9
Lung 3.8±0.1 7.3±0.8 14.7±1.3 39.4±4.5
Kidney 2.6±0.1 2.5±0.1 2.7±0.1 3.1±0.9
Muscle 0.2 0.3 0.4 0.1
Tumor 1.1±0.1 N/A N/A 7.5
Unit: %total injection
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Chapter 7. EFFECTS OF DRUG TREATMENTS DETERMINED BY PROCA1-AFFIBODY 
7.1 Introduction 
As described in Chapter 1.2, two common anti-cancer drugs, Herceptin, and Erlotinib 
which overate via the same HER pathway will be selected [153, 167] (Figure 1-1). Herceptin 
(trastuzumab) is a humanized antibody that targets the extra-cellular domain of HER2/Neu 
[168].  Herceptin is a clinically approved antibody against HER2 in breast and ovarian cancers. 
While the drug is well studied in treating breast cancer clinically, it is important to determine 
whether treatment of HER2/Neu positive cancer with Herceptin will lead to any changes in 
HER2 levels and distribution in tumors [83]. Erlotinib is a tyrosine kinase inhibitor of EGFR and 
can promote tumor regression in various xenograft models [169]; it can also be used to treat 
the mammary tumor cells which are EGFR positive [170]. In the treated cancer cells, the EGFR 
level will be down regulated [171]. Since the erlotinib is an inhibitor to the kinase site in the 
intracellular domain of EGFR family, the trastuzumab is an antibody against the extracellular 
domain of HER2. The two drugs can be applied together to cancers [172]. The Herceptin and 
ProCA1-affi342m have different epitope on HER2 extracellular domain [173], which enables the 
detection of HER2 expression in tumors by ProCA1-affi342m. 
In this chapter, drug effects on the HER2 receptor expression levels were examined us-
ing cultured cancer cells such as SKOV-3 and MDA-MB-231. The drug of Herceptin was chosen 
because it is a targeting drug for HER2. The dosage of 5 µM was used based on the estimated 
tumor cell numbers and reported receptor level (Chapter 1.2.3). 
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7.2 Results and discussion 
7.2.1 Both receptor level and cell survival decrease after been treated by Herceptin 
Before measured by MRI, we confirmed the effects of drug treatment in the cell level by 
ELISA, western blotting and flowcytometry. For ELISA and western blotting, the cells were 
treated with Herceptin for 3 and 5 days. Then the cells were lysed and the cell lysis was de-
tected by antibody against ProCA1-CD2m. Both results (Figure 7.1 and 7.2) indicate that the to-
tal receptor decreased up to 35%. The receptor change may due to two factors: first Herceptin 
may cause cell death so that the total number of cancer cells will decrease; second the expres-
sion level of HER2 will also decrease on treatment. 
 
Figure 7.1 ELISA assay to monitor the HER2 receptor level changes after being treated 
with Herceptin in SKOV3 cells. 
 1 day: seed cells to 6 well plates (5000) 2 day: add 4 pmol Herceptin (3 times receptor) 
4-6 day: change medium and add another 4 pmol Herceptin Cell lysate was collected at day 4 
and day 6. 
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Figure 7.2 Western blotting results indicated that the total receptor number decreased 
about 35% after five days of treatments with Herceptin 
 
 
 
7.2.2 Monitoring the receptor change after drug treatment using flow cytometry 
In order to detect whether the expression level of HER2 is changed due to drug treat-
ment, flowcytometry is also used to measure the receptor change. In each measurement 2×104 
cells of treated and non-treated samples were counted and the total fluorescent intensity was 
measured. The receptor was detected by HER2 antibody and ProCA1-affi342 respectively (Fig-
ure 7.3). Both detections show the receptor level change up to 10% percentage (Figure 7.4). 
However the ProCA1-affi342m detection sensitivity is much lower than antibody detection. This 
may due to an extra primary antibody need to be added to detect ProCA1-affi342m during 
sample preparation.  
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Figure 7.3 Drug treatment measued by flow cytometry 
The cells were seeded in 10 cm dishes, and treated with Herceptin (5 nM) during the 5-
day period. After 5 days, the cells were harvest and stained. Finally, 2x104 cells were counted 
and the fluorescent intensity was measured by flow cytometry. The x-axis is fluorescent intensi-
ty. The y-axis is cell numbers been counted with staining. 
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Figure 7.4 Flow cytometry demostrated the receptor level change after being treated 
with Herceptin.  
Both antibody and CA1-affibody can show the difference of cells after drug treatment. 
Due to the extra step by adding CA1 antibody, the sensitivity is lower of CA1-affibody than anti-
body.  
 
 
7.2.3 ProCA1-affibody can monitor the total receptor change in cancer cells by MRI 
Based on previous data, we confirmed that ProCA1-affi342m is able to monitor the re-
ceptor change in cell level by immune techniques. Then we further add Gd-ProCA1-affi342 to 
the drug treated cells and measured by MRI. Figure 7-5a shows that when cells are treated by 
various concentration of Herceptin, the receptor change will be different. We selected the 
highest treatment concentration 50 µM of Herceptin to measure the effects on different time 
points (Figure7-5b). After 5 days treatment, the MRI intensity of cell samples is lower than non-
treated samples and those with 3 days treatment. Since MRI is not a sensitive technique, and 
each scanning only counts 1 mm thickness of the sample, this makes the intensity change not 
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significant. When repeat this measurement in the future, the detection will be integral of up to 
1 cm thickness of the samples.  
 
Figure 7.5 MR images of SKOV3 cells after various days of treatments by Herceptin 
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Chapter 8. MONITORING CHANGES IN BIOMARKERS OF DISTRIBUTIONS AND EXPRESSION 
LEVELS DURING BREAST CANCER PROGRESSION BY TARGETED PROTEIN BASED CON-
TRAST AGENTS 
8.1 Introduction 
Breast cancer is one of the diseases with highest occurrence in North America. The 
death rate is the second among different cancers [174]. There are several breast cancer types 
categorized based on its origination from ducts or lobules [175]. Table 8 lists different types of 
the breast cancers and their origination or properties. For example, Infiltrating Ductal Carcino-
ma (IDC) is the most common type of breast cancer representing 78% of all malignancies[176].   
Among these cancer types with different morphologies (Figure 7-1), cancer originated 
from Ductal Carcinoma In-Situ (DCIS) is an invasive type of early breast cancer occurs inside of 
the ductal system[177]. The development of breast cancer is a multi-step process that initiates 
as premalignant atypical hyperplasia, transforms into pre-invasive DCIS, and progresses into 
invasive breast cancer[178-179]. With a proportion of 20—30% among all the breast cancers, 
DCIS turned to be a common type of breast cancer [180].  Currently, the clinical management of 
DCIS patients is still controversial, mainly because the natural development of DCIS is largely 
unknown [181]. Molecular basis on why and how often DCIS progresses to potentially lethal in-
vasive breast cancer remains to be determined. Therefore, understanding the key molecular 
events in initiation and progression of DCIS should allow the identification of biomarkers for 
specific therapy to achieve the maximized efficacy of treatment as well as determining molecu-
lar targets for the development of new treatment approaches for DCIS.  
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 Table 10 Table of different breast cancer types 
 
 
Breast Cancer Type Characteristics 
Ductal Carcinoma in situ (DCIS) The cancer cells are inside the ducts but have not spread 
through the walls of the ducts into surrounding breast. 
Lobular Carcinoma in situ (LCIS) It begins in the milk producing glands but does not grow 
through the wall of the lobules. 
Infiltrating Ductal Carcinoma 
(IDC) 
The cancer cell starts in a milk passage (duct) of the breast, 
breaks through the wall of the duct and grows into the 
fatty tissue of the breast. 
Infiltrating Lobular Carcinoma 
(ILC) 
ILC starts in the lobules as LCIS. It can spread to other parts 
of the body. About 10% of invasive breast cancers are ILC. 
Triple-negative breast cancer This type of breast cancer whose cells lack estrogen 
receptors and progesterone receptors, and do not have 
overexpression of HER2 on the cell membrane. 
Medullary Carcinoma This special type of infiltrating breast cancer has a rather 
well defined boundary between tumor tissue and normal 
tissue. 
Metaplastic Carcinoma This is a very rare type of invasive ductal cancer. They 
include cells that are normally not found in the breast. 
Mucinous Carcinoma This type of breast cancer is formed by mucus-producing 
cancer cells. The prognosis is better than other types of 
invasive breast cancers. 
Tubular Carcinoma They are called tubular because of the way the cancer cells 
are arranged when seen under microscope. It accounts 
about 2% of all the breast cancers. 
Papillary Carcinoma The cells of these cancers tend to be arranged in small, 
finger-like projections when viewed under the microscope. 
Adenoid cystic Carcinoma These cancers have both glandular and cylinder-like 
features when seen under the microscope. 
Phyllodes tumor This rare breast tumor develops in the stroma of the 
breast, which is a connective tissue. 
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Figure 8.1 Histological special breast cancer types 
(A) Tubular carcinoma, (B) cribriform carcinoma, (C) classic invasive lobular carcinoma, 
(D) pleomorphic invasive lobular carcinoma, (E) mucinous carcinoma, (F) neuroendocrine carci-
noma, (G) micropapillary carcinoma, (H) papillary carcinoma, (I) low grade invasive ductal carci-
noma with osteoclast-like giant cells. 
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Figure 8.2 Progression of DCIS tumors 
The progression stages of DCIS tumors show morphology changes as the DCIS tumor 
proceeds to the invasive tumors [176]. 
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There are several biomarkers such as HER2, EGFR, estrogen (ER) and progesterone re-
ceptor (PR), which have been identified for the diagnostics of breast cancers (Figure 8.1).  The 
breast carcinoma has been classified into subtypes based on the molecular classification [182]. 
For example, Infiltrating Lobular Carcinoma (ILC) is often positive for estrogen (ER) and proge-
sterone receptor (PR) [183]. ER has overexpression in about 70% of breast cancers since the 
binding of estrogen to ER may cause proliferation of mammary cells [184]. PR also expressed in 
most of the breast cancer cells, however, for most ER negative breast cancers are often PR neg-
ative [185]. The biomarker of EGFR family has the advantages because they express on the cell 
membrane which benefits for the tumor targeting diagnosis and therapy. 
The EGFR family also plays an important role in the breast cancers via the signaling 
pathway to regulate the cell progression, survival and differentiation [186].  About 70% percent 
of the DCIS tissues with high proliferation rate demonstrate a high expression level of EGFR or 
HER2 [187]. It has been shown that 14 to 91% of human breast carcinomas express a high level 
of the EGF receptors[186]. Most of the DCIS tissues identified is associated with a high prolife-
ration rate, which is negative for estrogen receptor, and expresses high levels of EGFR or 
HER2/neu[187].  The importance of EGFR signaling in the growth of DCIS tissues is further sup-
ported by study results obtained from examination of the effects of an EGFR inhibitor, erlotinib, 
on human DCIS tissues xenografted in nude mice. Inhibition of EGFR induced apoptosis and de-
creased the growth of human DCIS tissue xenografts by 56% [188-189].  However, only 8% of 
non-basal-like breast cancers are EGFR positive [190].  
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Figure 8.2 shows that basal type human breast cancer cell line MCF-10 DCIS produces 
rapidly growing lesions in nude mice with predominant ductal carcinoma in situ (DCIS) charac-
teristics of human DCIS during the first three weeks of tumor growth and gradually progressing 
to invasive tumor in 4 to 8 weeks.  HER2/Neu is found in all DCIS lesions, whose expression is 
absent or very low in invasive tumor areas. In contrast, EGFR is not found in luminal tumor cells 
but only positive in the basal layer of the DCIS lesions. However, microinvasive lesions and inva-
sive tumor areas express a very high level of EGFR, suggesting the role of EGFR signal in devel-
oping a basal type invasive breast cancer.  To date, the role of EGFR family of proteins, including 
EGFR and HER2, in the progression of DCIS is still unclear. 
Dr. Fred R. Miller at Wayne State University School of Medicine, Detroit, MI, developed 
the MCF10 series of cell lines that were originally derived from benign breast tissues from a 
woman with fibrocystic diseases [180, 191-194]. These cell lines exhibit distinct histopathologi-
cal features of the progression from normal, to atypical hyperplasia, to DCIS and then to inva-
sive breast cancer.   MCF10A is a normal immortalized human mammary epithelial cell line with 
low levels of EGFR, ER, survivin and a wild type p53 gene. An H-ras–transformed derivative 
MCF10AT contains mostly premalignant cells. It has been shown that inoculation of MCF10AT 
cells into athymic mice produces sporadic DCIS and invasive cancers (25%) in about a year. A 
clonal cell line cultured from a MCF-10AT derived tumor xenograft, MCF10DCIS.com (or MCF-10 
DCIS), produces rapidly growing lesions in about three weeks with predominant comedo DCIS 
characteristics, such as tightly packed tubular structures with central necrosis, distinct intact 
basement membrane surrounding each ductular structure containing luminal tumor cells with 
large and vesicular nucleoli, high mitotic figures and moderate foamy cytoplasm (Figure 7-4). In 
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this specific xenograft model, tumor progression has been observed by staining several bio-
markers, like HER2, EGFR and ER with IHC. Based on these studies and our designed contrast 
agents targeting to biomarkers, we used the ProCA1-affi342 to image the xenograft tumor of 
MCF10-DCIS model at the early stage. We will also use ProCA1-affi342 and ProCA1-affi1907 to 
monitor the biomarker changes in different prognosis stages. 
Dr. Lily Yang’s lab has provide the orthotopic tumor model and her work on MCF10A 
cancer progression model has been described in Figure 8.3 and with other biomarkers like ER 
and PR been analyzed.  
We previous have shown that HER2 targeted MRI contrast agents have been developed 
(discussed in Chapters 3.7). As discussed in Chapter 1.4 and developed by a Sweden group [195], 
affibody, which is a small protein with 58 amino acids, can target to EGFR or HER2 with a high 
affinity (nM in Kd) and function as a ligand. In addition, affibody will not activate receptors like 
antibody [74]. At the same time affibody does not need post-translational modification, which 
makes it easy to express in E. coli. 
In this study, we are going to first develop EGFR targeted MRI contrast agents based on 
the targeting capability of affibody 1970 to against EGFR. In addition, we will apply MRI based 
contrast agents ProCA1-affibody342 against HER2 and ProCA1-affibody1907 against EGFR to 
monitor the expression level of HER2 and EGFR respectively in various tumor stages of xeno-
graft mouse model. Furthermore, we will monitor the receptor changes after treated with can-
cer drugs like Herceptin and Erlotinib by the designed MRI contrast agents. 
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Figure 8.3 EGFR and HER expression levels in a human breast cancer xenograft derived 
from a  basal type of breast cancer cell ine (MCF-10DCIS)  
The EGFR and HER2 expression level changes in early and late stages of MCF-10DCIS tu-
mors. The expression level of EGFR increases as the tumor progress to invasive stage. And the 
distribution of EGFR extends. The HER2 expression decreased obviously. (Provided by Dr. Lily 
Yang) 
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8.2 Results and discussion 
8.2.1 Biomarker changes during the prognosis 
Based on the IHC results from Dr. Lily Yang’s group, we already found that in the xeno-
grafted MCF10-DCIS model, the HER2 expressed in the whole tumor area within the the basal 
layer of the DCIS lesions in the early pre-invasive stage. The EGFR was found mainly on the bas-
al layers of the DCIS tumors at this stage. After 3-4 weeks, when the tumor turns into invasive 
tumors, the expression level of HER2 decrease dramatically; however, the EGFR expression in-
creased in the whole invasive tumor tissue. 
 
8.2.2 Generation of EGFR targeted contrast agent 
The ProCA1-affi1907 was created by fusion of affibody ZEGFR1907 which can specifically 
target to EGFR [71]. The epitope locates in helix 1 and 2 with 13 amino acids (Figure 8.4). This 
three helix protein which consists of 58 amino acids were cloned to the C-terminal of ProCA1-
CD2 with a GGSGG linker in between. In the fused protein ProCA1-affi1907, there is one Gd3+ 
binding site in ProCA1-CD2 which can function as an MRI contrast agent [196]. The affibody 
ZEGFR1907 keeps the helix structure with the EGFR binding sites exposed.  
 
 
Figure 8.4 Sequence of ProCA1-affibody-EGFR 
 
151 
Same as the parental protein ProCA1-CD2, the constructed ProCA1-affi1907 was also 
expressed in E.coli and subsequently purified by GS-4B column for GST fusion protein. In order 
to apply this fusion protein in cells and animal experiments, PEGylation was also used to modify 
this protein, since PEGylation can increase the relaxivity and stability of the fusion protein. An 
optimized PEG size of 40 repeated PEG units was used for better tumor penetration and keep-
ing the tumor binding capability. 
We next examined whether ProCA1-affi1907 can specifically target to EGFR in cancer 
cells with high EGFR expression.  Two cancer cell lines were used for immunostaining. One is 
breast cancer cell line MDA-MB-231, which overexpresses EGFR but HER2 negative. Another 
one is an ovarian cancer cell line SKOV-3, which overexpresses both EGFR and HER2. The paren-
tal protein ProCA1-CD2 was used as a negative control. Binding of the Gd-ProCA1-affi1907 to 
the selected cells was analyzed by immuno-fluorescence staining using the polyclonal antibody 
against PEGylated parental protein ProCA1 (PAbPGCA1) (Figure 4.13). A substantial staining in-
tensity of ProCA1-affi1907 bound to MDA-MB-231 cells was observed and increased as incuba-
tion concentration increased. In contrast, the cells stained with ProCA1-CD2 demonstrated very 
week binding. In SKOV-3 cells, it showed the same phenomena as MDA-MB-231 (Figure 8.5). 
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Figure 8.5 ELISA of cell binding with EGFR high expression 
The ProCA1-affi1907 of different concentration was incubated with cancers with differ-
ent expression level of EGFR. The breast cancer cell line MDA-MB-231 has highest expression 
level as indicated. SKOV-3 also shows high expression level of EGFR. MCF-7 is an EGFR negative 
cell line.  
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Figure 8.6 Immunostaining of cancer cells by ProCA1-affibody-EGFR 
The EGFR positive cell line MDA-MB-231 was used for cell staining. ProCA1-CD2 was 
used as control. 
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Figure 8.7 Immuno staining of ProCA1-affi1907 in SKOV-3 cancer cells 
SKOV-3 cells also have high expression of EGFR 
 
8.2.3 MR imaging of orthotopic tumors 
We then tested whether our designed contrast agent would result in MRI contrast en-
hancement in xenograft orthotopic models of MCF-10DCIS human cancer cell lines. The con-
trast agent Gd3+ ProCA1-affi342 at concentration of 3 mM (100 fold lower than clinically-
approved contrast agent DTPA was administrated via the tail vein (80 µl). Pre- and post-
contrast MRI were collected at different time points using T1 and T2 weighted fast spin echo or 
T1 weighted gradient echo sequences. The mice were imaged using two pulse sequences: the 
T1 and T2 weighted fast spin echo sequence (TR=2 s, TE=0.022 or 0.066 s) and the T1 weighted 
gradient echo sequence (TR=0.088 s, TE=2 ms and P=0.009 s). The fields of view are 3 cm×3 cm 
with matrix of 256 × 256 and slice of 1 mm in thickness. Image J was used to quantitatively ana-
lyze the MRI images obtained. The regions of interest (ROI) were selected by circling the tumor 
sites. Then the signal intensities of the ROIs were calculated and compared. Six adjacent slides 
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were selected to measure signal changes which were averaged to obtain statistical significant 
results. At 3 hour time point, the tumor site exhibited significant contrast enhancement.  Strong 
contrast enhancement was observed in the tumor 24 hours after injection. Such MRI contrast 
enhancement was decreased after 24 hrs post injection (Figure 7.4-6).  In Figure 7.6, the tumor 
showed enhancement in edge area, however, the center of the tumor was still dark as pre-scan. 
These results demonstrated the heterogeneous structure of tumor. 
 
Figure 8.8 MRI of orthotopic model.  
Tissue or organ grafts may be transplanted to their normal situation in the animal. 
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Figure 8.9 MRI of orthotopic tumor model with fast spin echo 
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Figure 8.10 MRI of orthotopic tumor model with gradient echo 
 
 
8.2.4 MRI can monitor distribution of biomarkers 
 
The biomarker may not only have expression level change during the progression and 
drug treatments, the morphology or the distribution of biomarkers may also change inside the 
tumor [13]. IHC can clearly demonstrate the distribution of biomarker in the tumor (Figure 
8.11) by staining both the biomarker, like HER2 and nucleus. Since MRI is a technique with high 
resolution [197], we expect to use our designed MRI contrast agents to monitor the tumor 
structure (Figure 8-10). At the time point of 24 hr, when most contrast agents concentrated in 
the tumor area, the heterogeneous structure can be viewed (Figure 8.10). Figure 8-11 shows 
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the difference of MRI signal in the edge and core part of the tumor. This MRI results confirms 
the biomarkers like HER2 detected by ProCA1-affi342 inside the tumor area is heterogeneous. 
The MRI is able to image the structure of the tumor; however, the resolution is not as high as 
IHC to give the information of the distribution of HER2. The DCE-MRI (Dynamic Contrast En-
hancement) is expected to give more information about the biomarker changes. [198]  
 
 
Figure 8.11 MR images can demonstrate the structure difference at the edge and core of 
the tumor 
The tumor edge with lipids shows brightness after loaded with MRI contrast agents. The 
inner heterogeneous structure can also be viewed by MRI with high resolution. 
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Figure 8.12 Tumor structure can be measured by MRI and IHC 
Slide 3 shows the tumor structure of the edge area. Slide 8 shows the structure in the 
core area. 
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Chapter 9. OTHER CONTRAST AGENTS WITH MULTIPLE METAL BINDING SITES 
To further increase the contrast capability, protein-based MRI contrast agents with mul-
tiple Gd3+ binding sites have been engineered, expressed and characterized. New generation of 
protein-based contrasts, named ProCA2 and ProCA3, has two to four Gd3+ binding sites on sin-
gle protein. Figure 9.3 shows that tail vein injection of 0.02 mmol/kg ProCA32 (~10 folds lower 
dosage (0.02 mmol/kg) than that of Gd-DTPA (0.2 mmol/kg) resulted in an enhancement of 
blood, liver and kidney 50 min post injection under MRI scanner. The blood circulation time is 
much longer than small molecular contrast agents, which indicates that ProCA32 could be po-
tentially used as a blood pool contrast agent. The enhancement of tissue completely disap-
peared two days after injection, which indicates that our contrast agent could be completely 
secreted out after two days. 
 
9.1 Designing HER2 targeted contrast agent by using mutated CaM as host protein 
(ProCA22-affi342) 
After the first generation of protein contrast agent series with ProCA1-CD2 as host pro-
tein, we also linked tumor targeted peptide affibody ZHER2:342 to other designed contrast agents 
with multiple metal binding sites. Calmodulin with four metal binding sites has been designed 
and grafted to be Gd3+ binding protein. Affibody ZHER2:342 was grafted into the loop region of 
CaM and the fusion protein is named ProCA22-affi342. Initial data showed that this designed 
contrast agents is able to target to cancer cells with high expression of HER2. 
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9.2 Toxicity of protein based contrast agents 
The acute toxicity of contrast agent on liver enzymes (ALT, ALP, AST, LDH), urea nitro-
gen, bilirubin, and total protein from CD1 mice 48 hours post-contrast agent injection were 
found to be negligible compared to a control subject (CD-1 mice). No acute toxicity was ob-
served for mice (N > 10) after contrast agent injection, suggesting that our contrast agent is 
likely to maintain its metal complex stability and strong affinity for Gd3+ in vivo.  
The toxicity of the designed protein was analyzed with CD-1 mice. No acute toxicity was 
observed following tail vein injections of 4-fold greater dosages than that currently used in MRI, 
evaluated over a 2-day test period. Characterization of serum samples from the test mice re-
ceiving the agent detected no apparent damage to kidney, liver, or heart (Table 11). 
 
Table 11 Acute Toxicity of ProCA1-affi342 
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Figure 9.1Measurement of creatinine concentration in mouse blood 
Creatine is a nitrogenous organic acid which provide energy mainly for muscle. No ob-
vious change has been observed by measuring the concentration in mouse blood. 
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Figure 9.2 The enzyme in liver of ALT (alanine aminotransferase) and ALP(Alkaline Phos-
phatase) activity 
Decreasing of ALP has been observed indicates that the protein based contrast agents 
accumulate mainly in liver. 
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Figure 9.3 Metal concentration in blood has been measured 
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Chapter 10. CONCLUSIONS AND MAJOR DISCOVERIES  
Magnetic Resonance Imaging (MRI) is one of the primary oncological imaging modality 
capable of high resolution 3-dimensional imaging, exquisite soft tissue contrast with body 
depth without use of ionized radiation [164-166]. In addition, it enables the non-invasive and 
repetitive assessment of biological processes of the same living subject at different time points 
for monitoring treatment response and disease progression [78-79, 199-201]. Molecular imag-
ing of cancer biomarkers using MRI potentially improves our understanding of the disease and 
drug activity during preclinical and clinical drug treatment [202-205]. However, lack of desired 
MRI contrast agents capable of enhancing the contrast between normal tissues and tumors 
with high relaxivity, tumor targeting, high intratumor distribution and no toxicity is one of the 
major barriers for the application of MRI to assess specific biomarkers for diagnosis and moni-
tor drug effect.   
Biomarkers such as the epidermal growth factor receptors EGFR and HER2/Neu are 
highly expressed in various diseases such as breast and ovarian cancers and play important 
roles in disease progression and survival. They are also major drug targets for targeted therapy. 
Since the clinical application of targeted therapy is largely limited because current methods for 
assessment of these cancer biomarkers involve invasive methods, such as biopsy and the effec-
tiveness of the target therapy largely depends on the pre-selection of patients over-expressing 
these biomarkers. To date, one of five HER2/Neu clinical tests, including biopsy and immunos-
taining (IHC), provides incorrect results, leading to improper selection of appropriate patients 
for personalized treatment using biomarker targeted therapies [34, 64]. There is an urgent need 
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to develop non-invasive and accurate methods for diagnosis and selection of patients and to 
monitor biomarker levels/distribution and their changes upon treatment by targeted drugs.  
In this dissertation, we developed novel protein based MRI contrast agents by fusion of 
affibody variants to the C-terminal of ProCA1-CD2. The results indicated that ProCA1-affi342 
and ProCA1-affi1907 are able to target to HER2 and EGFR respectively. MRI and NIR imaging 
have been demonstrated to prove the capability of using the protein based contrast agents to 
monitor tumors types, tumor progression and drug treatments. 
The targeted protein contrast agents were designed and generated by gene cloning. In 
vitro results showed that ProCA1-affi342 is well folded after GST purification. PEGylation of the 
ProCA1-affi342 not only increased the stability and decreased the immunogenicity, but also im-
proved the metal binding and relaxivity. The metal binding affinity to Gd3+ is up to 1.86 pM and 
the relaxivity with r1 and r2 of 21 and 30 mM-1s-1 exhibited. In order to compensate the short-
age of MRI with low sensitivity, a NIR dye Cy5.5 was successfully conjugated to the ProCA1-
affi342 at the C-terminal. Spectra from UV-absorbance, MS and NMR confirmed the conjuga-
tion. All the in vitro measurements and results demonstrate that the ProCA1-affi342 is well de-
signed as an MRI contrast agent, which will be able to generate dual signals of MRI and NIR in 
vivo. (Chapter 3) 
After measuring the in vitro properties of ProCA1-affi342, the tumor binding capability is 
also evaluated in the cell assays. Several immune assays like western blotting, ELISA, immunef-
luorescent staining and flowcytometry have been used and detected by self generated antibody 
against ProCA1-CD2 (PAb-ProCA1-CD2). The results are consistent and show significant binding 
of ProCA1-affi342 to the HER2 overexpressed cancer cells. Besides monitoring the ProCA1-
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affi342 by protein and protein interaction, the retention of ProCA1-affi342 in tumor cells was 
also measured by monitoring the Gd3+ signals with MRI and radioactive assay.  The results 
showed that Gd3+ chelated in the ProCA1-affi342 can be retained in the tumor cells compared 
with the free Gd3+. This ex vivo studying in the tumor cells provided good knowledge of ProCA1-
affi342 for further studying in the tumor mouse. (Chapter 4) 
In order to apply our contrast agents to tumor mice, the mouse model was carefully es-
timated and selected.  Subcutaneous xenografted model was selected for the initial studying. 
Two tumor cell lines SKOV-3 and MDA-MB-231 with different HER2 expression level and mod-
erate tumorigenicity were chosen. The MRI results clearly showed that the ProCA1-affi342 tar-
geted to the HER2 positive SKOV-3 tumor specifically. The tumor got highest MRI intensity after 
1 day injection with highest concentration of ProCA1-affi342 concentrated in this tumor site. 
Some primary organs like kidney and liver also got enhancements. MRI blocking results also 
supported this results that the ProCA1-affi342 accumulated in the positive tumor site specifical-
ly by the biomarker HER2 targeting. Further studying of IHC is consistent with the MRI results 
which show the ProCA1-affi342m accumulating in the positive tumor sites. The IHC results also 
show that ProCA1-affi342m has better tissue penetration and distribution than HER2 antibody. 
(Chapter 5) 
Since the MRI enhancement has been observed in the positive tumor sites and some 
other primary organs like kidneys and liver, further quantitative results of on the distribution of 
ProCA1-affi342m are analyzed by NIR intensity, radioactive assay and ICP-OES. The NIR moni-
tors the protein signal since the dye is covalently conjugated to the ProCA1-affi342. The ra-
dioactive assay and ICP-OES monitors the Gd3+ signals. By these two methods to monitor the 
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biodistribution, we can see that about 20% of ProCA1-affi342m accumulates in the positive site, 
however only less than 10% of Gd3+ stays in the tumor site after one day injection. We may 
conclude that since some disassociation of Gd3+ from ProCA1-affi342, the free Gd3+ will be se-
creted out of the body in short time. The pharmokinetics of ProCA1-affi342m needs to be stu-
died in the future. (Chapter 6) 
After been proved that the ProCA1-affi342 has the capability to target to HER2 overex-
pressed tumors both in vitro and in vivo, further application of this contrast agent has started. 
First, we tried to use this contrast agent to monitor the effects of drug treatments. In Chapter 7, 
the receptor level changes have been detected by ProCA1-affi342 in cancer cells with both im-
munology techniques and MRI. Further studying of relaxivity changes related to the drug 
treatments in cells and the tumor changes in mouse model will be taken to better use ProCA1-
affi342 with high relaxivity and tumor targeting capability. (Chapter 7) Second, we also try to 
use these protein contrast agents to monitor the tumor progression. A new type of contrast 
agent ProCA1-affi1907 has been generated to target to EGFR. Since in the specific tumor model 
MCD10-DCIS, both the biomarkers HER2 and EGFR will change during the progression, we may 
use our contrast agents to view the receptor level change and distribution change. Some initial 
work has been done with ProCA1-affi342m. The results showed that ProCA1-affi342m is able to 
bind to the orthotopic tumor with MCF10-DCIS in the early stage. We will continue this re-
search by using both ProCA1-affi342m and ProCA1-affi1907 to monitor the tumor in early and 
late stage to see the biomarker changes. (Chapter 8) 
In this dissertation, targeted protein based contrast agents have been generated and all 
the experimental conditions have been optimized, so that we first time successfully got the MRI 
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enhancement in the tumor model by tail vein injection of our contrast agents. This also paved 
the way for other contrast agents with multiple metal binding sites (Chapter 9). However, in 
order to apply our contrast agents clinically, there is still a long way in front; we are continuing 
this project by estimate the lowest dosage needed, the long term toxicity and other physiology 
researches. The capability to spatially and temporally visualize as well as quantify HER2 and 
EGFR would significantly improve our capability to follow the expression of these biomarkers 
during tumor progression and metastasis, monitor treatment efficacy, aid in drug selection for 
patients, and further apply and develop novel targeted therapy. 
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Appendix I 
Establish mammalian expression and purification of HER2-ECD 
In this dissertation, we focused a lot on quantitative analysis of biomarkers with various 
techniques. In order to get quantitative results, pure biomarker proteins are needed to be a 
standard. Dr. Leahy in Johns Hopkins kindly provided stable cell line LEC1 with transfaction of 
the HER2-ECD gene in pSGH vector [206]. This HER2-ECD is also His-tag fused. The LEC1 cell was 
first thawed and cultured in α-MEM medium with 10% of FBS. After passaged to T250 flasks for 
2 days, the medium was changed to DMEM/F12 medium with 1% FBS. This medium was 
changed every three days and collected to obtain the secreted HER2-ECD. The expression level 
was measured by western blotting (Figure A1).  The HER2-ECD was purified from cell culture 
medium by His-tag column (Figure A3).  
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Figure A 1 Monitoring HER2-ECD expression by western blotting 
 
 
Figure A 2 Expression level of HER2-ECD was measured by ELISA 
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Figure A 3 Elution curve of HER2-ECD purification 
 
 
Figure A 4 Purity of HER2-ECD was detected by SDS-PAGE gel 
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Appendix II  
  Vaccine and Monkey virus 
Introduction 
Vaccinia virus is a member of the Poxviridae family, which is capable of causing severe 
systemic human disease [207]. Since the vaccinia virus contains some of the largest, most com-
plex and most challenging viruses, it has been well characterized. It is a classic subject for viral 
studies. Other members of this family include variola virus, which is the cause of smallpox, 
monkeypox virus, cowpox virus and ectromelia virus. All these viruses are in distinguish in mor-
phology and cross-reactive antigenically. Therefore, any one of them confers some protection 
against other members of the family.  
In this virus family, both the monkeypox and smallpox can cause infections on human. The 
monkeypox was observed when the smallpox had been eradicated [208]. Their signs and symp-
toms are very similar although the viruses are significantly different. In order to diagnose the 
monkeypox, several methods based on protein are used currently [209]. The significance of 
protein has provided ways to diagnose post viral infection and tool for epidemic analysis. Fur-
thermore, the development of potential vaccine and new monoclonal antibodies are identified 
and characterized. But because of the similarity between monkeypox and smallpox, it is difficult 
to diagnose monkeypox or smallpox correctly by clinical presentation alone [210]. So we are 
going to find the selectivity of monoclonal antibodies against different virus. Our work will be 
based on the structural knowledge of viral fusion proteins. 
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     A27L is one of the viral fusion proteins. The wide type protein sA27L is a vaccinia virus 
envelope protein encoded by the A27L gene. This protein contains 110 amino acids, which can 
be divided into four domains. The residues 1-20 form a signal peptide for protein processing; 
the second region including residues 21-32 is a lysine/arginine rich region, which is essential for 
binding to cell surface GAGs (glycosaminoglycans); the third region contains residues 43-84, 
which is coiled-coil structure involving self-assembly; and the last C-terminal sequence has inte-
raction with another viccinia virus protein A17L [210]. A29L is the orthologous gene of A27L 
gene, which is also called A27Lo.  
       As a virus protein, the A27L protein as well as the A27L gene is involved in the im-
mune activities. The A27L gene with other virus genes in same family protects nonhuman pri-
mates against lethal monkeypox as a DNA vaccine. The other virus genes include L1R, A33R and 
B5R, in which the L1R is specific to IMV, A33R and B5R is specific to the EEV. The previous in vi-
vo experiments demonstrated that the A27L or B5R alone couldn’t protect significantly, while 
the combination of these genes made a high level of protection from challenge. Furthermore, 
the virus genes also have a combinational activity with the subdomains of the virus proteins. 
There are open reading frames of the virus proteins: A27Lo, A33Ro, B5Ro and L1Ro (o refers to 
ortholog). These subunits were expressed firstly by deleting the transmembrane region of the 
A27L, A33R, B5R and L1R genes respectively. Results showed that both the genes and protein 
products alone failed to generate high level antibodies. However, the DNA vaccine boosted by 
the subunit of its protein product induces high immune response [208].  
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Different antibodies may bind to different epitopes of antigens. The structure of the epi-
tope contains lot information that benefits for preventing, diagnosing and curing diseases [211]. 
There are mainly two types of epitopes: linear and conformational epitopes. A linear epitope 
means the antibodies bind to antigen by recognizing its sequence of amino acids or primary 
structure [209]. Site directed mutation, western blotting, immunohisto- chemistry and ELISA 
can be applied to study the linear epitope. However, some of these techniques may not be 
suitable for conformational epitope research. For example, the protein samples boiled, treated 
with beta-mercaptoethanol are denatured; as a result, the samples may fail to keep their origi-
nal three-dimensional conformation. Therefore, site mutation and western blotting cannot be 
applied strictly. In order study the conformational epitope, the three dimensional structure of 
the proteins should be studied. The best choice probably is to study the crystal structure of an-
tibody-antigen structure [212]. The complex structure will show the accurate relationship of 
antibody and antigen when binding together. NMR is also a powerful technique to study pro-
tein structure, while large molecular weight of antibody (150KDa) hinders its application. How-
ever, it is possible to study the structure of CDR domain in antibody and small antigen by NMR. 
Then special software can be used for docking the structure between antibody and antigen 
[213]. 
The amino acids sequence of protein A29L is highly conserved. The sequences of A27L 
and A29L are as following [209]: 
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Figure A4 Sequences of monkey virus family proteins 
 
         The antibodies against monkeypox virus react with the orthologs of this virus. So 
the orthologous gene of A27L was cloned from the monkeypox virus [214]. Because of the high 
identity, only specific antibodies can identify A27L and A29L. The monoclonal antibody mAB 
126-69-3-7 can recognize A29L with high specificity. The monoclonal antibody VVIV 4B4-2-1 on-
ly recognizes A27L. The mAB 126-69-3-7 is supposed to recognize the coil-coiled region of A29L. 
It is a conformational epitope. Therefore, we will use site mutation, SPR, Western Blot, CD, 
Mass Spectrum, NMR and other techniques to study the structure of A29L and the epitopes of 
the antibodies against A29L both in polymer and monomer.  
 
Materials and Methods 
Mini-scale expression 
      Competent cells BL21 were transformed with pET-A29L, pET-A27L-4M and pET-A27L-
2M; and selected for growth on the Luria broth (LB) ampicillin plates overnight. The individual 
clone was used to inoculate in 200ml LB culture containing 100ug/ml ampicillin. The cells were 
grown overnight at 37°C to saturation. Then 50ml of the cells were used to inoculate into 1L LB 
medium with 100ug/ml ampicillin. The cells were grown at 37°C continuously. When the OD600 
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got 0.6, 1mM IPTG was added to induce the expression. Cells were harvest by centrifugation 
(7K, 20min). The precipitation was suspended by the lysate buffer (Tris) and sonicated com-
pletely. Then the emulsion was centrifuged (14K, 40min) and the supernatant was ready for pu-
rification.  
 
Purification of A27L mutants and A29L 
         The supernatant was harvest and filtered by the 0.45um membrane. Then the su-
pernatant was applied to 2ml Ni2+-chelating affinity column. 20mM, 100mM and 250mM imida-
zole were added into the washing buffer (PBS) to elute the fusion protein. The fraction obtained 
from affinity purification was dialyzed by the buffer of 100mM Tris-HCl, pH7.4 and then loaded 
onto Superdex-G75 gel filtration and SP cation exchanging columns in consequence for further 
purification. The samples in each step were detected by SDS-PAGE with coomassie blue staining. 
After detecting, the parts of interest were collected and dialyzed by the 100mM Tris buffer 
again to store the protein. 
 
Binding analysis by surface plasmon resonance 
        The protein A29L was immobilized on the CM5 sensor chip directly. Then the anti-
body mAB 126-69-3-7 in different concentrations flows over the chip with A29L. Then the anti-
body will be immobilized on the chip by covalent bonds. Different concentration of virus pro-
teins flowing through the chip with antibody give different signal changes based on their bind-
ing affinity and concentration. 
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Site-directed mutagenesis 
         The A27L gene was cloned to pET-21 vector before. Four mutants called N27A T30A 
Y39A and G40A are made from A29L using site-directed mutagenesis. Four pairs of primers 
were used: N27A Forward 5-GCTAAAGCTCCAGAGACTAAACGC-3, Reverse 5-AGCCTTTGTAGAAA 
AAAATTCAGT-3; T30A Forward 5- CCAGAGGCTAAACGCGAAGCAATT-3, Reverse 5-
CTTTTTAGCAGCCTTTGTAGAAAA-3; Y39A Forward 5- AAAGCCGCTGGAGACGACAATGAG-3, Re-
verse 5- AACAATTGCTTCGCGTTTAGTCT-3; G40A Forward 5- AAAGCCTATGCAGACGACAATGAG-3, 
Reverse 5-AACAATTGCTTCGCGTTTAGTCT-3. After phosphorylation, the primers were used in 
PCR to obtain mutated DNA. The anneal temperature is set to 60 °C. Then the whole PCR prod-
ucts were used in transformation in DH5a cell lines. Two single clones on the ampicillin plate 
are picked out and inoculated in 10ml LB medium. Plasmid DNA is extracted by mini prepera-
tion and sent to sequence. After getting the correct sequences, the plasmid DNA is transferred 
to BL21 competent cells and used to do expression. 
 
Results and Discussions 
The SPR binding curves have been showed in figure 1.  The protein A29L has specific 
binding with the antibody mAb 126-69-3-7. The binding affinity is much higher than A27L (Data 
not shown).  The binding of the two mutants was tested to check the epitope of the antigen. 
The Mass Spectra have been tested on the virus proteins and their mutants. The results indicate 
that all of the virus protein exists in trimer.  Figure 1 shows the PCR products of A27L mutants. 
The mutant M4 contains four amino acids being mutated: K27N A30T D39Y E40G; the mutant 
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M2 contains two amino acids being mutated: V61I R74H. The bands are solid and there is no 
other non- specific product. After extracting the DNA from agarose gel and mini preparation of 
plasmid DNA, the sequences are right after DNA sequencing.  
 
 
 
 
 
 
 
 
 
      Figure A5. Mutation of A29L 
1,2 N27A  3,4 T30A  5,6 Y39A  7,8 G40A 
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Figure A6. SPR spectra of A27L mutations to the antibody mAb 126-69-3-7 
 
 
 
Figure A7 Mass spectra of virus proteins 
All the SPR and MS data are provided by Dr. Yiming Ye in CDC 
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Summary  
Currently, the virus proteins A27L, A29L and the mutants M4, M2 have been expressed 
and purified. Some basic characters, like CD and SPR, also have been measured on these pro-
teins. However, we are trying to find the epitope of mAb 126-69-3-7 and whether the epitope 
depends on the polymers. Based on the hypothesis, we use Biacore to measure the binding of 
mAb 126-69-3-7 with A27L, A29L, M4 and M2 both in polymer and monomer.  The current re-
sults show that the mutant M4 has specific binding with the antibody, which means the epitope 
exists on the region of M4. Therefore, further mutation has been designed to study the exact 
epitope. Also fresh samples, which exist in monomer will be prepared to determine the func-
tion of trimer in supporting the epitope. 
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